

Igor A. Parshikov

*Microbial Transformation of
Nitrogen Containing Heterocycles*

Igor A. Parshikov

**Microbial Transformation of Nitrogen
Containing Heterocycles**

Primedia E-launch LLC

Reviewers:

Khasaeva F.M., Sc.D.

Zaraisky E.I., Ph.D.

Recommended for publication by the Academic Council of the Institute of Applied Mechanics, Russian Academy of Sciences

Igor A. Parshikov. Microbial Transformation of Nitrogen Containing Heterocycles. – Dallas: Primedia E-launch LLC, 2016. – 130 p.

The monography describes examples of the application of microbial technologies for obtaining of derivatives from a series of nitrogen heterocycles (saturated nitrogen heterocycles, azaarenes and quinolones). It is proposed alternative ways for synthesize substances that are difficult to obtain by the methods of organic chemistry. Microbial technologies of synthesis of organic compounds may find out a practical application in the production of various drugs.

ISBN 978-1-68419-830-6

© Igor A. Parshikov, 2016

Introduction

Microbial conversions of organic compounds has applications in many fields. Chemical, pharmaceutical and biotechnology industries draw on microbiological methods for synthesis of compounds that are difficult to obtain by the methods of organic chemistry alone (Petersen and Kiener 1999; Parshikov et al. 2012; Parshikov et al. 2014; Silva et al. 2014). Nitrogen-containing heterocyclic rings serve as key moieties of many drugs. In the last 15 years, several reviews of the microbial transformation of nitrogen-containing heterocyclic compounds, such as azaarenes and quinolones, have been published (Hüttel and Hoffmeister 2010; Petersen and Kiener 1999; Sukul and Spiteller 2007; Vickers and Polsky 2000).

In this monography, data from the literature on nitrogen-containing heterocyclic compounds have been compiled. For example, mitomycin C shows antibiotic and antitumor activities that have been related to the aziridine ring (Fürmeier and Metzger 2003), and aziridine derivatives are used in the synthesis of anti-malarial drugs (D'hooghe et al. 2011; Ghorai et al. 2007; Fattorusso and Taglialatela-Scafati 2009; Wright et al. 2002; Pacorel et al. 2010; Seebacher and Weis 2011; Richardson and Wyso 1960; Faber 2004; Baker 1987; Duran et al. 2000).

Pyridine rings are found in the bisphosphonate drugs risedronate and zoledronate, used to treat bone diseases (Gatti and Adami 1999), the antimycobacterial prodrugs isoniazid, ethionamide, and prothionamide (Deretic et al. 1996; Wang et al. 2007), and other antibacterial, anticancer, and antimalarial compounds (Kumar et al. 2008; Prachayasittikul et al. 2009; Ge et al. 2010; Duran et al. 2000; Ahmad et al. 2001; Petersen and Kiener, 1999; Rui et al. 2005; Hüttel and Hoffmeister 2010; Faber 2011; Rajini et al. 2011; Takayama et al. 2010; Saliba and Kirk 1998; Kaur et al. 2010; Rocco 2003; Achan et al. 2011; Baird 2011; Vale et al. 2009; Peters 1999; Vale et al. 2009; Brocks and Mehvar 2003).

Hybrid antimalarial drugs, such as those combining the structure of quinine with artemisinin (Walsh et al. 2007) or those combining derivatives of 4-aminoquinoline with a 1,2,4-trioxane or a 1,2,4-trioxolane (Coslédan et al. 2008; Araújo et al. 2009; Chauhan et al. 2010; Muregi and Ishih 2010), may have more antimalarial activity than their components. Other derivatives of quinoline have been used for the treatment of tuberculosis (Andries et al. 2005) and for pain relief (Gomtsyan et al. 2005). The isoquinoline alkaloids include morphine and many other drugs (Petersen and Kiener 1999; Banasik et al. 1992; Waring et al. 1975; Refaie et al. 2005; Gomtsyan et al. 2005; Taggart et al. 1948; Guetzoyana et al. 2009; Araújo et al. 2009; Jones et al.

2009; Kalkanidis et al. 2002; Boibessot et al. 2002; Agarwal et al. 2005; Kontnik and Clardy 2008; Kaur et al. 2009; Resnick et al. 1993; Zefirov et al. 1993; Parshikov et al. 1994b; Kaiser et al. 1996; Fetzner 1998; Petersen and Kiener 1999; Willumsen et al. 2005; Rajini et al. 2011).

Bacterial enzymes involved in azaarene hydroxylation include naphthalene 1,2-dioxygenase (Ensley et al. 1983; Resnick et al. 1993), quinaldine 4-oxidase (Stephan et al. 1996), carbazole 1,9a-dioxygenase (Inoue et al. 2006), biphenyl 2,3-dioxygenase (Resnick et al. 1993), and toluene dioxygenase (Boyd et al. 2002). Bacterial aldehyde oxidases (Yasuhara et al. 2002) and cytochromes P450 (Kelly et al. 2003) may transform azaarenes to the corresponding lactams (Vickers and Polksy 2000). Fungi may also produce cytochromes P450 that transform azaarenes to lactams; some fungi, such as *Beauveria bassiana*, *Aspergillus* spp., and *Cunninghamella* spp., are especially useful for drug biotransformations because of the regio- and stereospecificity of their enzymes (Grogan and Holland 2000; Lehman and Stewart 2001).

The quinolones are a large group of synthetic compounds that have been developed as antimicrobial agents (Ball, 2000b). They are used extensively in human clinical and veterinary medicine for treating diseases caused by Gram-negative and Gram-positive bacteria (Oliphant and Green, 2002; Andersson and

MacGowan, 2003; Dalhoff and Schmitz, 2003). Their antibacterial effectiveness is due to their inhibition of DNA gyrase (topoisomerase II) activity in Gram-negative bacteria and topoisomerase IV activity in Gram-positive bacteria (Drlica and Zhao, 1997; Brighty and Gootz, 2000; Cattoir and Nordmann, 2009). Some quinolones also have antitumor, antiviral (against hepatitis B and C, HIV and herpes viruses), antiallergic, anti-tubercular, immunomodulatory, and antidiabetic activity (Boteva and Krasnykh, 2009; Mugnaini et al., 2009; Kloskowski et al., 2010). Quinolones may even be effective against different types of malaria parasites (Mahmoudi et al., 2003).

The differences in molecular structure and in activities of quinolones in vitro are the basis for their classification (Ball, 2000; King et al., 2000; Schellhorn, 1998; Oliphant and Green, 2002). Antimicrobial activities of first-generation quinolones (i.e., nalidixic acid, oxolinic acid, cinoxacin, piromidic acid, pipemidic acid, and flumequine) are excellent against aerobic Gram-negative bacteria, but not against aerobic Gram-positive bacteria and anaerobic bacteria. In 1980 came the second generation of quinolones, when norfloxacin was synthesized by introducing a fluorine atom at position 6 of the 4-quinolone molecule and a diamine, piperazine, in position 7 (Brighty and Gootz, 2000). These modifications make possible the antimicrobial activity of quinolones against aerobic Gram-positive bacteria, as well as to

increase their activity against Gram-negative bacteria. Second-generation quinolones include ciprofloxacin, ofloxacin, enoxacin, fleroxacin, lomefloxacin, pefloxacin and rufloxacin (Andersson and MacGowan, 2003; Andriole, 2000). However, the second generation of quinolones still did not have activity against anaerobic bacteria. Subsequently, quinolones of the third generation, such as grepafloxacin, gatifloxacin, sparfloxacin, enrofloxacin, danofloxacin, and pradofloxacin, effective against Gram-positive bacteria, particularly pneumococci, were developed and had high activity against anaerobic bacteria (Andriole, 2000). The fourth-generation quinolones (e.g., trovafloxacin, clinafloxacin, sitafloxacin, moxifloxacin, and gemifloxacin) have high activity against anaerobes and pneumococci (Andriole, 2000; Andersson and MacGowan, 2003).

Involvement of microbial technologies in the modification of quinolones will provide chemists and pharmacologists with unique derivatives. These may have novel therapeutic properties for the treatment of many bacterial diseases and even parasitic diseases, such as malaria (Mahmoudi et al., 2003). Most of the biotransformation processes that have been developed for quinolones use fungi [Wetzstein et al., 2010], but a few of them use bacteria (Kieslich et al., 1973; Chen et al., 1997; Adjei et al., 2006). In addition to the microbial transformations of the quinolones, those of some naphthyridones (including nalidixic

acid), pyranoacridones (including acronycine), and cinnolones (cinoxacin) will be considered.

Chapter 1. Microbial transformation of saturated nitrogen-containing heterocyclic compounds

Organic chemists and pharmacologists have a great interest in the stereochemistry and regiochemistry of synthetic processes (Hassner 2009), such as the molecular stereochemistry of aziridines (Keifer et al. 1988) and the hydroxylation of azetidine, pyrrolidine, and their derivatives (Romanova et al. 1995; Feula et al. 2010).

Some mono- and bi-cyclic polyhydroxylated alkaloids are known as potent glycosidase inhibitors; for instance, castanospermine and deoxynorjirimycin are promising anti-cancer and anti-HIV compounds, respectively. Some stereoisomers of 2-(hydroxymethyl)pyrrolidine-3,4-diols also have been reported as glycosidase inhibitors (Ahn and Shin 1997). The 3-hydroxypyrrrolidine moiety is found in a range of naturally occurring bioactive alkaloids and many synthetic approaches to produce 3-hydroxypyrrrolidines also have been developed (Aurrecoechea et al. 2009; Hodgson et al. 2006; Rios et al. 2007).

Many hydroxylated piperidine alkaloids are potent inhibitors of glycosidases and related enzymes (Grishina et al. 2011). 4-Hydroxypiperidines are present in many drugs, such as the antidiarrhoeal loperamide and the schizophrenia medications haloperidol and benztropine (McKay et al. 2010). Polyhydroxypiperidines and polyhydroxyazepanes have attracted

attention of researchers due to their biological importance in the development of glycosidase inhibitors (Shih et al. 2007; Shih et al. 2011).

Azocanes used in the asymmetric synthesis of α -alkylated α -amino acids also demonstrate potential biological activities as potent inhibitors of some enzymes (Georg and Guan 1992).


Microbial technologies for hydroxylation in different positions of molecules may help in creating a series of new drugs; for instance, hydroxylated derivatives of saturated nitrogen-containing heterocycles may be obtained using microbial technologies and used to create hybrid molecules of artemisinin, quinine, or chloroquine (Walsh et al. 2007).

1.1. Microbial transformation of aziridine derivatives

Aziridine groups are three-membered ring structural elements, found in a wide variety of natural products that have antibiotic and antitumor properties (Thibodeaux et al. 2012). The aziridines have been targets of investigation for synthetic chemists, both as useful intermediates and as final products (Chawla et al. 2013). Compounds having a 5-(aziridin-1-yl)-2,4-dinitrobenzyl structure were shown to have significant growth-inhibitory properties against *Trypanosoma brucei* and *Trypanosoma cruzi* (Bot et al. 2010). Clean reactions of the aziridine compounds that

have exceptionally good regioselectivity and/or stereoselectivity are desirable (Chawla et al. 2013).

Racemic aziridine-containing carbonitriles (**I**, Ar – substituted aryl) are separated into the corresponding carboxylic acids (**II**) and enantiopure isomers (**Ia**) by *Rhodococcus erythropolis* AJ270 with yields of 45-50% (Dexian and Meixiang 2010):




1.2. Microbial transformation of azetidine derivatives

The azetidines are saturated nitrogen heterocycles containing a four-membered ring. Derivatives of azetidines have been used in traditional Asian medicine for over a thousand years (Diethelm and Carreira, 2013). The skeleton of 2-azetidinone is the pharmacophore of a widely employed class of antibiotics, the β -lactam antibiotics (penicillins, cephalosporins, carbapenems, monobactams, and penems) (Sharma et al. 2011). The metabolism of nitrogen heterocyclics may lead to lactam formation.


Among the saturated nitrogen heterocycles, there is great interest in the transformation of monocyclic β -lactams, since they

often have antimicrobial activity. Furthermore, 3-azido-, 3-amino- and 3-(1,2,3-triazol-1-yl)- β -lactams have been synthesized and studied as drugs against *Plasmodium falciparum* (Singh et al. 2011). A bifunctional hybrid structure based on 7-chloroquinoline and a β -lactam recently was synthesized as a potential antimalarial agent (Singh et al. 2012).


Transformation of a monocyclic β -lactam (**III**) by a growing culture of the fungus *Beauveria bassiana* ATCC 7159 produces a hydroxy derivative (**IV**) with a yield of 10%; a second product (**V**) with a yield of 20% is formed by elimination of the benzyl radical (Archelas et al. 1988):




Biotransformation of an α -keto- β -lactam (**VI**) with growing cells of *Saccharomyces cerevisiae* for five days produces both the *cis*-hydroxy derivative (**VII**, 62% yield) and the *trans*-hydroxy derivative (**VIII**, 38% yield) (Mihovilovic et al. 2005):




The conversion of azetidine-2-carboxylic acid (**IX**) by a hydrolase from *Pseudomonas* sp. A2C forms 2-hydroxy-4-aminobutyric acid (**X**) (Gross et al. 2008):




Hydroxylation of *N*-substituted azetidines (**XI**, R=CO₂C₆H₅; CO₂*t*-Bu) by cells of the bacterium *Sphingomonas* sp. HXN-200 leads to the formation of hydroxy derivatives (**XII**, R=CO₂C₆H₅; CO₂*t*-Bu) in position 3 of the heterocyclic ring with yields of 91-98% (Chang et al. 2002):




Later, it was shown that the resolution of racemic 1-benzylazetidine-2-carbonitriles (**XIII**, R=C₆H₅; 4-Me-C₆H₄; 4-MeO-C₆H₄; 4-Br-C₆H₄; 3-Br-C₆H₄; 2-Br-C₆H₄) in phosphate buffer by *R. erythropolis* AJ270 produces isomers **XIV** and **XV** with yields up to 46% (Leng et al. 2009):



XIII




XIV




XV

1.3. Microbial transformation of pyrrolidine and its derivatives

Pyrrolidine forms a part of the molecule of an antibiotic, clindamycin, which has antimalarial properties (Bertrand and Kremsner 2002). Furthermore, pyrrolidine derivatives inhibit the growth of chloroquine-resistant strains of *P. falciparum* (Mendoza et al. 2011). There are several pharmacologically interesting compounds with the general formula (XVI) (Archelas et al. 1986):



XVI




XVII


They can also be regarded as analogs of γ -amino- β -hydroxybutyric acid (XVII), which has great medical importance (Archelas et al. 1986).

N-Substituted pyrrolidines and their analogs may be hydroxylated by growing cultures of *B. bassiana* ATCC 7159. As



a result of the transformation of 1-benzylpyrrolidone-2 (**XVIII**), optically active 1-benzyl-5-hydroxypyrrolidone-2 (**XIX**, 12% yield) and benzaldehyde (**XX**, 2% yield) are formed (Srairi and Maurey 1987):




During the transformation of 1-benzoylpiperidone-2 (**XXI**), the optically active 1-benzoyl-4-hydroxypiperidone-2 (**XXII**, 21% yield) has been detected in a mixture with benzamide (**XXIII**) (Srairi and Maurey 1987):



In the transformation of 1-benzoylpiperidine (**XXIV**) by *B. bassiana*, however, a carbon atom at position 2 is hydroxylated with ring opening and formation of *N*-(4-hydroxybutyl)benzamide (**XXV**, 8% yield) (Archelas et al. 1986):




During the transformation of 1-benzoylpyrrolidine (**XXIV**) or 1-benzoylpyrrolidone-2 (**XXI**) in growing cultures of the fungus *Cunninghamella verticillata* VKPM F-430, the optically active (-)-1-benzoyl-3-hydroxypyrrolidine (**XXVI**, 38% yield) or benzamide (**XXIII**), respectively, is produced (Parshikov et al. 1992; Parshikov et al. 2010a,b):




3-Hydroxy derivatives in yields of 66.4-93.5% also are formed in the transformation of *N*-substituted pyrrolidines by cells of the bacterium *Sphingomonas sp.* HXN-200; the substituent on the nitrogen atom may be CH₂C₆H₅, COC₆H₅, CO₂CH₂C₆H₅, CO₂C₆H₅, or CO₂*t*-Bu (Li et al. 2001).

During hydroxylation of 1-phenacylpyrrolidone-2 (**XXVII**) by *B. bassiana* ATCC 7159, an intermediate compound, 1-phenacyl-5-hydroxypyrrolidone-2 (**XXVIII**), and the final


product, 1-phenacylpyrrolidinedione (**XXIX**), are formed with a yield of 23% (Srairi and Maurey 1987):



Further study of the biotransformation of substituted pyrrolidones in growing cultures shows that *B. bassiana* ATCC 7159 hydroxylates 5-methyl-1-benzoylpiperidone-2 (**XXX**) in either position 3 (**XXXI**, 11% yield) or position 4 of the hetero ring (**XXXII**, 12% yield), in a process accompanied by the formation of benzamide (**XXIII**) (Srairi and Maurey 1987):



Separation of racemic *trans*-pyrrolidine-2,5-dicarboxamides (**XXXIII**, R= Bn; allyl; H), using the amidase of *R. erythropolis* AJ270, produces (2*S*,5*S*)-pyrrolidine-2,5-dicarboxamides (**XXXIV**) and (2*R*,5*R*)-5-carbamoylpiperidone-2-carboxylic acids (**XXXV**) in high yields (up to 52%) with excellent enantioselectivity (Chen et al. 2012):




1.4. Microbial transformation of piperidine and its derivatives


Some substituted piperidine rings are found in natural and synthetic compounds that have biological activity (Sun et al. 2000). Over the past 20 years, thousands of piperidine derivatives have been tested in pre-clinical and clinical studies (Weintraub et al. 2003), and some piperidine derivatives, such as febrifugine, are antimalarial drugs (Taniguchi and Ogasawara 2000).

In recent decades, the microbial chemistry of piperidines has flourished. Studies of the transformation of 1-benzoylpiperidine (**XXXVI**) by various research groups under different experimental conditions have resulted in the isolation of 1-benzoyl-4-hydroxypiperidine (**XXXVII**) with a yield of 18% after transformation with *B. bassiana* ATCC 7159 (Johnson et al. 1968a); 7% after transformation with *B. bassiana* ATCC 7159

(Archelas et al. 1986); 80% after transformation with *Aspergillus niger* VKM F-1119 (Parshikov et al. 1992); and 91–98% after transformation with *Sphingomonas sp.* HXN-200 (Chang et al. 2002):




After the transformation of 1-benzoylpiperidine (XXXVI) by growing cultures of *B. bassiana* VKM F-3111D and *Penicillium simplicissimum* KM-16, 1-benzoyl-4-hydroxypiperidine (XXXVII) was isolated with yields of 60% and 3%, respectively, and the optically active (+)-3-hydroxy-1-benzoylpiperidine (XXXVIII) with yields of 1% and 3%, respectively (Parshikov et al. 1992). Furthermore, among the biotransformation products of 1-benzoylpiperidine (XXXVI) produced by *P. simplicissimum* KM-16, 2-hydroxy-1-benzoylpiperidine (XXXIX) was detected with a yield of 12% (Parshikov et al. 1992):




Transformation of 1-(4-acetylphenyl)piperidine by *B.*

bassiana ATCC 7159 was similarly accompanied by the formation of 4-hydroxy-1-(4-acetylphenyl)piperidine with a yield of 20% (Johnson et al. 1992). Later, this result was confirmed by others (Osorio-Lozada et al. 2008).


With the introduction of a methyl substituent on the heterocyclic ring, the transformation process is different. In the transformation of 1-benzoyl-4-methylpiperidine (**XL**) in growing cultures of *B. bassiana* ATCC 7159, a 4-hydroxy compound (**XLI**, 13% yield) is obtained with 1-benzoyl-4-hydroxymethylpiperidine (**XLII**, yield 23%) (Johnson et al. 1969):





At the same time, 1-benzoyl-3-methylpiperidine (**XLIII**) is hydroxylated in position 4 (**XLIV**, yield 6%) and position 3 of the heterocyclic ring (**XLV**, 7% yield) (Johnson et al. 1969):




For a compound with two methyl substituents on the heterocyclic ring, 1-benzoyl-2,5-dimethylpiperidine (**XLVI**), the hydroxylation by *B. bassiana* ATCC 7159 occurs in position 3 of the ring (**XLVII**, 49% yield) (Johnson et al. 1969):




The introduction of a ketone group to the heterocyclic ring partially changes the site of hydroxylation. During growth of *B. bassiana* ATCC 7159 in the presence of 1-benzylpiperidone (**XLVIII**), in addition to 1-benzyl-4-hydroxypiperidone-2 (**XLIX**, 10% yield), the unstable 1-benzyl-6-hydroxypiperidone-2 (**L**, 5% yield) was detected but then was spontaneously converted to its dehydration product (1-benzyl-2-oxo-1,2,3,4-tetrahydropyridine) (**LI**) (Archelas et al. 1986):




During 1-benzoylpiperidone-2 (**LI**) hydroxylation in growing cultures of *B. bassiana* ATCC 7159, along with benzamide (**XXIII**), the optically active 1-benzoyl-4-hydroxypiperidone-2 (**LIII**) was isolated with a yield of 27% (Archelas et al. 1986):




During the transformation of 1-benzyl-3-methyl-Δ³-piperidine (**LIV**) by growing mycelia of *C. verticillata* VKPM F-430, three products were observed in a ratio of **LV**: **LVI**: **LVII** = 1:2:16 (Terent'ev et al. 1997):




LIV



LV




LVI




LVII


Other analogs of 1-benzyl-3-methyl- Δ^3 -piperidine (**LIV**), 1,2,5,6-tetrahydropyridines (**LVIII a** = R¹=Bn; R²=H; **b** = R¹=Bn, R²=H; **c** = R¹=Pr, R²=Me), were also converted by *C. verticillata* VKPM F-430 with formation of the isomers **LIX a** (97.6% yield), **LIX b** (100% yield), **LIX c** (19.0% yield), and **LX c** (59.0% yield) (Terent'ev et al. 2003):



LVIII a, b, c




LIX a, b, c




LX c

Also, in growing cultures of *C. verticillata* VKPM F-430, 2-acetoxymethyl-l-methyl-1,2,5,6-tetrahydropyridine (**LXI**) was

transformed into a 4-hydroxy derivative (**LXII**) with a low yield (Modyanova et al. 1999; Modyanova et al. 2010):



LXI




LXII

1.5. Microbial transformation of azepane, azocane and their derivatives

Azepane


Over the past 50 years, transformations of azepane (hexamethyleneimine) derivatives have been studied by several groups of researchers (Seebacher and Weis 2011).

During the transformation of 1-benzoylhexamethyleneimine (**LXIII**) by growing cultures of *B. bassiana* ATCC 7159, two optically active 3- and 4-hydroxy derivatives (**LXIV**, 3% yield; **LXV**, 11% yield) and a ketone (**LXVI**, 10% yield), with a carbonyl group at position 3 of the heterocyclic ring, are obtained (Archelas et al. 1986):




Other authors (Johnson et al. 1968a) reported that *B. bassiana* ATCC 7159 oxidizes 1-benzoylhexamethyleneimine (**LXIII**) to a mixture of 3- and 4-oxo-1-benzoylhexamethyleneimines (**LXVI** and **LXVII**) and the 4-hydroxy derivative (**LXV**).


Transformation of 1-(4-tolylsulfonyl)-hexamethyleneimine (**LXVIII**) by *B. bassiana* ATCC 7159 was accompanied by formation of only the 4-oxo derivative (**LXIX**) (Johnson et al. 1968a):




The bacterium *Gulosibacter molinativorax* ON4 oxidizes molinate (**LXX**) in several stages: azepane-1-carboxylic acid (**LXXI**), hexamethyleneimine (**LXXII**), and caprolactam (**LXXIII**), followed by the opening of the hetero ring (Barreiros et al. 2008):




Transformation of 4-methyl-1-benzoylhexamethyleneimine (**LXXIV**) in growing cultures of *B. bassiana* ATCC 7159 produces an oxo derivative (**LXXV**, 11% yield) and a second product of oxidation (**LXXVI**, 29% yield) that has a hydroxymethyl group (Johnson et al. 1968a):



Increasing the complexity of the molecular structure of hexamethyleneimine may still lead to similar results. For example, transformation of 3-benzoyl-3-azabicyclo[3.2.2]nonane (**LXXVII**) by *B. bassiana* ATCC 7159 also produces hydroxy and oxo derivatives (**LXXVIII**, 50% yield and **LXXIX**, 22% yield) (Johnson et al., 1968b):




1-Benzylcaprolactam (**LXXX**) hydroxylation in cultures of *B. bassiana* ATCC 7159 produces two optically active isomeric hydroxy derivatives (**LXXXI** and **LXXXII**) (Archelas et al. 1986):



Azocane

Despite the fact that azocanes (and their derivatives) include drugs with antiviral and antimalarial properties (Hocart et al. 2011), such as reactivators of phosphorylated cholinesterases

(Radic et al. 2012), their microbiological transformations have rarely been investigated. During the transformation of 3-benzoyl-3-azabicyclo[3.2.2]nonane (**LXXXIII**) in growing cultures of *B. bassiana* ATCC 7159, only one product (**LXXXIV**, 60-70% yield) is detected (Johnson et al. 1968b):



Chapter 2. Microbial transformation of azaarenes


Many pharmaceutical drugs that contain azaarene structures, especially pyridine, quinoline, acridine, and indole, have been isolated from nature or synthesized (Khasaeva et al. 2014). Among the microbial transformation processes reviewed here, those that are perhaps of greatest interest produce regiospecifically and stereospecifically hydroxylated derivatives of azaarenes that may be useful in development of candidate drugs (Zefirov et al. 1993; 1995; Boyd et al. 2002). Carboxylated derivatives of azaarenes may also be valuable for the same purpose (Kiener 1992). It is likely that microbial technology will be used in the future to produce new derivatives of heterocyclic

compounds with novel and completely unexpected therapeutic properties.


2.1. Transformation of single-ring azaarenes

Pyridine

The transformation of pyridine (**LXXXV**) and its derivatives has been investigated with bacteria isolated mostly from soils (Kost and Modyanova 1979; Shukla 1984; Fetzner 1998). *Rhodococcus opacus* hydroxylates pyridine to 2-hydroxypyridine (**LXXXVI**) and 2,6-dihydroxypyridine (**LXXXVII**); and *Arthrobacter crystallopoietes* hydroxylates pyridine to 3-hydroxypyridine (**LXXXVIII**) and 2,3-dihydroxypyridine (**LXXXIX**) (Zefirov et al. 1993; 1994):




LXXXV LXXXVI LXXXVII



LXXXVIII LXXXIX


Further biotransformation of pyridine after hydroxylation by *A. crystallopoietes* and *R. opacus* may also include opening of

the ring (Zefirov et al. 1993; 1994). *Agrobacterium* sp. transforms 4-hydroxypyridine (**XC**) to 3,4-dihydroxypyridine (**XCI**) (Watson et al. 1974):




Alkylpyridines


Some fungi, including the insect pathogen *Beauveria bassiana*, oxidize α -, β -, and γ -picolines [2-methyl- (**XCII**), 3-methyl- (**XCIII**), and 4-methylpyridine (**XCIV**)] to the corresponding hydroxymethylpyridines (**XCV**, **XCVI**, and **XCVII**). The products are not further metabolized (Modyanova et al. 1990; Zefirov et al. 1993):



The methyl group of 3-methylpyridine can be oxidized by the bacterium *Pseudomonas putida*; the product is pyridine-3-carboxylic acid (**XCVIII**) (Kiener 1992). 4-Methylpyridine and 4-ethylpyridine (**XCIX**) are both hydroxylated at carbon 2 by another bacterium, *Pseudonocardia* sp., to produce 2-hydroxy-4-methylpyridine (**C**) and 2-hydroxy-4-ethylpyridine (**CI**), respectively (Lee et al. 2006):




Several fungi and bacteria are able to transform not only monoalkyl-, but also dialkylpyridines (Kost and Modyanova 1979; Kiener 1992). For example, *B. bassiana* cultures hydroxylate 2,6-lutidine (2,6-dimethylpyridine, **CII**) to 2-hydroxymethyl-6-methylpyridine (**CIII**), with a yield of 88%, and trace amounts of 2,6-dihydroxymethylpyridine (**CIV**) (Modyanova et al. 1990):




Another fungus, *Exophiala dermatitidis*, converts 2,6-lutidine to 6-methylpicolinic acid (6-methylpyridine-2-carboxylic acid, **CV**) (Yoshida et al. 2010).


The hydroxylation of 2,5-lutidine (2,5-dimethylpyridine, **CVI**) by *B. bassiana* leads to a mixture of 3-hydroxymethyl-6-methylpyridine (**CVII**) and 2-hydroxymethyl-5-methylpyridine (**CVIII**) (Modyanova et al. 1990):



CVI




CVII




CVIII


During the oxidation of 3,4-lutidine (3,4-dimethylpyridine, **CIX**) by *B. bassiana*, two isomers are formed; the yield of 3-hydroxymethyl-4-methylpyridine (**CX**) is significantly higher than that of 4-hydroxymethyl-3-methylpyridine (**CXI**) (Modyanova et al. 1990):



CIX




CX



CXI


The transformation of 5-ethyl-2-methylpyridine (**CXII**) and either 2-ethyl- or 4-ethylpyridine (**CXIII**) by *B. bassiana* produces an α -hydroxyethyl derivative (**CXIV**), a β -hydroxyethyl

derivative (**CXV**), and an *N*-oxide (**CXVI**) in each case (Vorobyeva et al. 1990):



Pyrazine and alkylpyrazines

Pyrazine (**CXVII**) is carboxylated by the bacterium *Rhodopseudomonas palustris* to produce pyrazinoic acid (**CXVIII**) (Sasikala et al. 1994); and 2,5-dimethylpyrazine (**CXIX**) is oxidized by *P. putida* to produce 5-methylpyrazine-2-carboxylic acid (**CXX**) (Kiener 1992):




2,3,6-Trimethylpyrazine can also be oxidized by *P. putida* (Kiener 1992); the bacterial transformation of alkylpyrazines and


other substituted pyrazines has been reviewed recently (Müller and Rappert 2010; Rajini et al. 2011).

Pyrrole and alkylpyrroles

Bacillus megaterium has been used to carboxylate pyrrole (**CXXI**) to pyrrole-2-carboxylate (**CXXII**) (Wieser et al. 1998):



CXXI




CXXII


In addition, the 2-methyl group of 2,5-dimethylpyrrole can be oxidized by *P. putida* (Kiener 1992).

Alkylpyrazoles

3,5-Dimethylpyrazole (**CXXIII**) can be oxidized to 5-methylpyrazole 3-carboxylic acid (**CXXIV**) by *P. putida* (Kiener 1992):



CXXIII




CXXIV


2.2. Transformation of quinoline, alkylquinolines, and isoquinoline

Quinoline


A variety of bacteria metabolize quinoline (CXXV) (Fetzner et al. 1998). *Moraxella* sp., *Nocardia* sp., *Pseudomonas diminuta*, and *Bacillus circulans* oxidize quinoline to 2-quinolinone (carbostyryl, CXXVI) and 6-hydroxy-2-quinolinone (CXXVII) (Grant and Al-Najjar 1976; Shukla 1987; Bott and Lingens 1991). *Rhodococcus* sp. transforms quinoline not only to 2-quinolinone and 6-hydroxy-2-quinolinone but also to 5-hydroxy-6-(3-carboxy-3-oxopropenyl)-2-pyridone (CXXVIII) and pyrano-2-one-(3,2b)-6-pyridone (CXXIX) (Schwarz et al. 1989):




CXXV



CXXVI



CXXVII




CXXVIII


CXXIX

The aerobic conversion of quinoline by *Comamonas* sp. resulted in the formation of five metabolites in 30 h, including 2-quinolinone, 6-hydroxy-2-quinolinone, 5,6-dihydroxy-2-


quinolinone (CXXX), 5-hydroxy-6-(2-carboxyethenyl)-2-pyridone (CXXXI), and 8-hydroxy-2-quinolinone (CXXXII) (Cui et al. 2004):



CXXX




CXXXI




CXXXII

Several *Pseudomonas* spp. transform quinoline to 2-quinolinone, 8-hydroxy-2-quinolinone, 8-hydroxycoumarin (CXXXIII), and 2,3-dihydroxyphenylpropionic acid (CXXXIV) (Shukla 1986; 1987; Schwarz et al. 1989; Aislabie et al. 1990; Kilbane et al. 2000):




CXXXIII




CXXXIV

P. putida converts quinoline to 3-hydroxyquinoline (CXXXV) and 8-hydroxyquinoline (CXXXVI), the quinoline *cis*-5,6- (CXXXVII) and *cis*-7,8-dihydrodiols (CXXXVIII), and anthranilic acid (CXXXIX) (Boyd et al. 1987; 1993):




The same bacterium produces enantiopure quinoline *cis*-5,6- and 7,8-dihydrodiols using toluene dioxygenase (Boyd et al. 2002). *Desulfobacterium indolicum* hydroxylates quinoline to 2-quinolinone and then to 3,4-dihydro-2-quinolone (**CXL**) under anaerobic conditions (Johansen et al. 1997; Licht et al. 1997). Quinaldine 4-oxidase purified from an *Arthrobacter* sp. oxidizes quinoline to 4-hydroxyquinoline (**CXLI**) (Stephan et al. 1996):




The fungus *Cunninghamella elegans* oxidized quinoline (**CXXV**) to quinoline N-oxide (**CXLII**) with a yield of 65% in 7 days (Sutherland et al. 1994a).

Alkylquinolines (including quinine)

The quinaldine 4-oxidase from *Arthrobacter* sp. oxidizes quinaldine (2-methylquinoline, **CXLIII**) to 2-methyl-4-quinolinone (**CXLIV**) (Stephan et al. 1996):




CXLIII




CXLIV


Pseudomonas sp. hydroxylates 6-, 7-, and 8-methylquinolines (**CXLV**, **CXLVI** and **CXLVII**) at unidentified positions (Aislabie et al. 1990) and *P. putida* hydroxylates 6-methylquinoline, probably at the 2-position (Rothenburger and Atlas 1993):



CXLV




CXLVI




CXLVII


Cunninghamella elegans transforms 6-methylquinoline to 6-hydroxymethylquinoline (**CXLVIII**), quinoline-6-carboxylic acid (**CXLIX**), and 6-methylquinoline-*N*-oxide (**CL**) (Mountfield and Hopper 1998):



CXLVIII




CXLIX



CL

The 6'-methoxylated cinchona alkaloid quinine (**CLI**), its diastereomer quinidine (**CLII**), and its non-methoxylated analogs cinchonidine (**CLIII**) and cinchonine (**CLIV**) may be metabolized by fungi and bacteria (Siebers-Wolff et al. 1993; Shibuya et al. 2003). The fungus *Xylaria* sp. metabolizes quinine, quinidine, cinchonidine, and cinchonine to the corresponding 1-*N*-oxides (**CLV**, yield 90%, **CLVI**, yield 71%, **CLVII**, yield 82%, and **CLVIII**, yield 52%), respectively, in two weeks (Shibuya et al. 2003):




CLI R=OCH₃

CLIII R=H

CLII R=OCH₃

CLIV R=H




CLV R=OCH₃

CLVII R=H


CLVI R=OCH₃

CLVIII R=H

Mycobacterium smegmatis produces quinidine 1-*N*-oxide from quinidine; and the fungus *Pellicularia filamentosa* produces cinchonidine 1-*N*-oxide from cinchonidine (Siebers-Wolff et al. 1993). The fungus *Microsporum gypseum* produces both of the possible *N*-oxides: quinine 1-*N*-oxide and quinine 1'-*N*-oxide (**CLIX**) from quinine, but *Cunninghamella echinulata* instead produces 3-hydroxyquinine (**CLX**) (Siebers-Wolff et al. 1993):




Quininone (**CLXI**) was reduced by the yeast *Hansenula anomala* var. *schneggii* to quinidine (yield 50%) in 7 days (Ray et al. 1983):




CLXI

The transformation of the synthetic antimalarial primaquine (**CLXII**) by the yeast *Candida tropicalis* produced two metabolites, including primaquine *N*-acetate (**CLXIII**, yield 3.9%) and a small amount of a primaquine dimer with a methylene bridge (**CLXIV**, yield 0.4%), in 13 days (Clark et al. 1984a):




CLXII



CLXIII

CLXIV


The bacterium *Streptomyces rimosus* also produces the acetylated derivative from primaquine, but the dimer it produces (CLXV) lacks the methylene bridge (Clark et al. 1984b):




CLXVI

Isoquinoline


Several bacteria metabolize isoquinoline (CLXVII) (Fetzner 1998). *Pseudomonas putida* converts it to 1-isoquinolinone (isocarbostyryl, CLXVIII), the *cis*-5,6- and 7,8-dihydrodiols (CLXIX and CLXX, respectively), and the 4-, 5-, and 8-hydroxyisoquinolines (CLXXI, CLXXII, and CLXXIII, respectively) (Boyd et al. 1987; 1993). Isoquinoline is also oxidized to 1-isoquinolinone by various other bacteria (Aislabie et al. 1989; Röger et al. 1990; Sutherland et al. 1998a) and by purified quinaldine 4-oxidase from *Arthrobacter* sp. (Stephan et al. 1996). *Cunninghamella elegans* oxidized isoquinoline to isoquinoline N-oxide (CLXXIV) with a yield of 3% in 7 days (Sutherland et al. 1994a).




CLXVII




CLXVIII




CLXIX




CLXX




CLXXI



CLXXII



CLXXIII




CLXXIV


2.3. Transformation of benzodiazines and benzothiazines

Quinoxaline


Quinoxaline (**CLXXV**) is converted to 2-quinoxalinone (**CLXXVI**), quinoxaline *cis*-5,6-dihydrodiol (**CLXXVII**), and 5-hydroxyquinoxaline (**CLXXVIII**) by *P. putida* (Boyd et al. 1987; 1993):




CLXXV



CLXXVI




CLXXVII




CLXXVIII

Streptomyces badius transforms quinoxaline to 3,4-dihydro-2-quinoxalinone (**CLXXIX**) and 2-quinoxalinone (**CLXXVI**) and *S. viridosporus* transforms quinoxaline to 1-methyl-2-quinoxalinone (**CLXXX**, yield 12%) and 2-quinoxalinone (yield 8%) (Sutherland et al. 1998a):




CLXXIX




CLXXX

Quinazoline


Quinazoline (**CLXXXI**) is converted by *Pseudomonas putida* to 4-quinazolinone (**CLXXXII**), quinazoline *cis*-5,6-dihydrodiol (**CLXXXIII**), and 5,6,7,8-tetrahydroquinazoline-*cis*-5,6-diol (**CLXXXIV**) (Boyd et al. 1987; 1993). It is oxidized to 4-quinazolinone by the quinaldine 4-oxidase from *Arthrobacter* sp. (Stephan et al. 1996) and further to 2,4-quinazolinedione (**C**, yield 4%) by *S. viridosporus* (Sutherland et al. 1998a). The fungus *Aspergillus niger* oxidizes quinazoline to both 4-quinazolinone and 2,4-quinazolinedione (Sutherland et al. 2011):




CLXXX




CLXXXI



CLXXXII



CLXXXIII




CLXXXIV


Cinnoline

Cinnoline (**CLXXXV**) is oxidized by the quinaldine 4-oxidase from *Arthrobacter* sp. to produce 4-cinnolinone (**CLXXXVI**) (Stephan et al. 1996). In contrast, *Cunninghamella*


elegans and *Aspergillus niger* oxidize it to both of the possible *N*-oxides, the 1-oxide and the 2-oxide (**CLXXXVII** and **CLXXXVIII**) (Sutherland et al. 1998b):




CLXXXV



CLXXXVI




CLXXXVII




CLXXXVIII

Phthalazine


Phthalazine (**CLXXXIX**) is oxidized to 1-phthalazinone (**CXC**) by the quinaldine 4-oxidase from *Arthrobacter* sp. (Stephan et al. 1996) as well as by whole cells of *S. viridosporus* (Sutherland et al. 1998a). The fungi *Fusarium verticillioides* (= *F. moniliforme*) and *A. niger* also oxidize it to 1-phthalazinone (Sutherland et al. 1999; 2011), but *Cunninghamella elegans* oxidizes it instead to phthalazine *N*-oxide (**CXCI**) (Sutherland et al. 1999):



CLXXXIX




CXC



CXCI

Benzothiazines


The microbial transformation of the anti-inflammatory drug meloxicam, a benzothiazine derivative (**CXCII**), by *Cunninghamella blakesleeana* produced three metabolites after 5 days: 5-hydroxymethylmeloxicam (**CXCIII**, 93% yield), 5-carboxy meloxicam (**CXCIV**, trace amounts), and an oxamic acid derivative of meloxicam (**CXCV**, yield 4%) (Prasad et al. 2009):



2.4. Transformation of benzoquinolines


Acridine

The transformation of acridine (benzo[*b*]quinoline, **CXCVI**) by *C. elegans* leads to the formation of acridine *trans*-1,2-dihydrodiol (**CXCVII**) with small amounts of 2-hydroxyacridine (**CXCVIII**) (Sutherland et al. 1994b):



CXXVI


CXXVII




CXXVIII

CXXIX


Acridine *cis*-1,2-dihydrodiol (**CXXIX**) is produced from acridine by a mutant strain of *Pseudomonas fluorescens* (Bianchi et al. 1997). *Sphingomonas* sp. metabolizes acridine to acridin-9-one (**CC**) (van Herwijnen et al. 2004). Acridine was transformed by growing cells of *Mycobacterium vanbaalenii*, however, to four metabolites: acridine *cis*-1,2-dihydrodiol (yield 1.1%), 4-hydroxyacridine (**CCI**, yield 5.4%), acridin-9-one (yield 1.1%), and 9,10-dihydroacridine (**CCII**, yield 55.2%) in 7 days (Sutherland et al. 2009):



CC




CCI




CCII

The partially hydrogenated 9-amino-1,2,3,4,5,6,7,8-octahydroacridine (**CCIII**) was transformed into an *N*-oxide

(CCIV) by a resting cell suspension of the fungus *Cunninghamella verticillata* VKPM F-430 with a yield of 90% (Parshikov et al. 1994a):




CCIII




CCIV

Phenanthridine


Phenanthridine (benzo[*c*]quinoline, CCV) is transformed by *Streptomyces viridosporus* to phenanthridin-6-one (CCVI, yield 25%) (Sutherland et al. 1998a). The fungus *Umbelopsis ramanniana* (*Mucor ramannianus*) transforms phenanthridine to phenanthridine *N*-oxide (CCVII) as well as phenanthridin-6-one (Sutherland et al. 2005):



CCV




CCVI




CCVII

*Benzo[*f*]quinoline*

Benzo[*f*]quinoline (CCVIII) is degraded, apparently via benzo[*f*]quinolin-2-one (CCIX), by *Mycobacterium gilvum* (Willumsen et al. 2001):




CCVIII




CCIX


U. ramanniana transforms benzo[f]quinoline to the *trans*-7,8-dihydrodiol (**CCX**), the *N*-oxide (**CCXI**), and 7-hydroxybenzo[f]quinoline (**CCXII**) (Sutherland et al. 2005):



CCX




CCXI




CCXII

Benzo[h]quinoline


U. ramanniana also transforms benzo[h]quinoline (**CCXIII**) to the benzo[h]quinoline *trans*-5,6-dihydrodiol (**CCXIV**), benzo[h]quinoline *trans*-7,8-dihydrodiol (**CCXV**), and 7-hydroxybenzo[h]quinoline (**CCXVI**) (Sutherland et al. 2005):




CCXIII



CCXIV



CCXV




CCXVI


2.5. Transformation of phenazine and phenothiazine

Phenazine

Phenazine 1-carboxamide (**CCXVII**) is transformed by cultures of *Aspergillus sclerotiorum*, via phenazine 1-carboxylic acid, to 3-hydroxyphenazine 1-carboxylic acid (**CCXVIII**) (Hill and Johnson 1969):




CCXVII




CCXVIII

Phenothiazine


The transformation of phenothiazine (**CCXIX**) by cultures of *Cunninghamella elegans* forms two metabolites, 3-hydroxyphenothiazine sulfoxide (**CCXX**) and phenothiazine sulfoxide (**CCXXI**) (Sutherland et al. 2001):



CCXIX




CCXX




CCXXI

During the transformation of *N*-acetylphenothiazine (**CCXXII**) by *C. verticillata*, five metabolites were formed: the intermediate phenothiazine, phenothiazine sulfoxide (yield 5%),


N-acetylphenothiazine sulfoxide (**CCXXIII**, yield 17%), phenothiazin-3-one (**CCXXIV**, yield 4%), and phenothiazine-*N*-glucoside (**CCXXV**, yield 4%) in 72 h (Parshikov et al. 1999):




CCXXII



CCXXIII




CCXXIV




2.6. Transformation of indole, carbazole, and the carbolines

Indole


Many bacteria transform indole (**CCXXVI**) by different pathways (Oshima et al. 1965; Fetzner 1998). In one classic pathway, the naphthalene 1,2-dioxygenase from *Pseudomonas putida* oxidizes indole to indole *cis*-2,3-dihydrodiol (**CCXXVII**), which loses water spontaneously to produce indoxylo (3-hydroxyindole, **CCXXVIII**), which then is oxidized in air to indigo (**CCXXIX**) (Ensley et al. 1983):




CCXXXVI



CCXXXVII




CCXXXVIII




CCXXIX


Other bacteria, including *Desulfobacterium indolicum* and some *P. putida* strains, transform indole to oxindole (2-indolinone, **CCXXX**), isatin (2,3-indolinedione, **CCXXXI**), and anthranilic acid (Johansen et al. 1997; Licht et al. 1997; Li et al. 2009):



CCXXX




CCXXXI




CCXXXII

Aspergillus niger converts indole to an indoxyll intermediate and then cleaves the heterocyclic ring to produce *N*-formylantranilic acid (**CCXXXII**) (Kamath and Vaidyanathan 1990). The mushroom *Pleurotus ostreatus* degrades indole via isatin (Ren et al. 2006).

The ergot fungus *Claviceps purpurea* transforms indole-3-acetic acid (**CCXXXIII**); the major product is 5-hydroxyindole-3-acetic acid (**CCXXXIV**) (Teuscher and Teuscher 1965):




CCXXXIII




CCXXXIV

In the transformation of 3-indolylacetonitrile (**CCXXXV**) by *Beauveria bassiana*, the main product was 3-methylindole (**CCXXXVI**, yield 46%) in 13 days (Boaventura et al. 2004):




CCXXXV




CCXXXVI

Tryptamine (**CCXXXVII**) was transformed by *A. niger* to 5-hydroxyindole-3-acetamide (**CCXXXVIII**, yield 24%) in 13 days (Boaventura et al. 2004):



CCXXXVII




CCXXXVIII

Carbazole


A great variety of bacteria metabolize carbazole (**CCXXXIX**), usually by a naphthalene-like oxidation of a ring carbon or by angular dioxygenation, to produce *cis*-dihydrodiols

(Bressler and Fedorak 2000; Larentis et al. 2011). In the first method, carbazole is transformed by *Pseudomonas* sp. using naphthalene 1,2-dioxygenase and by *Sphingomonas yanoikuyae* B8/36 using biphenyl 2,3-dioxygenase, presumably via a transient *cis*-dihydrodiol in both bacteria, to produce 3-hydroxycarbazole (**CCXL**) (Resnick et al. 1993). In the second method, *Pseudomonas resinovorans*, *Pseudomonas* sp., and *Nocardoides aromaticivorans* transform carbazole by angular dioxygenation using carbazole 1,9*a*-dioxygenase, via 2'-amino-2,3-dihydroxybiphenyl (**CCXLI**), to anthranilic acid and 2-hydroxypenta-2,4-dienoic acid (**CCXLII**) (Ouchiyama et al. 1993; Nojiri et al. 2001; Inoue et al. 2006):




CCXXXIX

CCXL



CCXLI




CCXLII

Pseudomonas sp. and *Flavobacterium* sp. transform carbazole via unknown pathways to indole-3-acetic acid and other

ring-cleavage products (Gieg et al. 1996; Obata et al. 1997). Using other pathways, *Ralstonia* sp. oxidizes carbazole to the 1-, 3-, and 9-hydroxycarbazoles (**CCXLIII**, **CCXL**, and **CCXLIV**, respectively) and to 3-hydroxy-1,2,3,9-tetrahydrocarbazol-4-one (**CCXLV**) (Waldau et al. 2009):




Aspergillus flavus transforms carbazole to 3-hydroxycarbazole, the main product, and small amounts of 1-hydroxycarbazole and 2-hydroxycarbazole (**CCXLVI**) in 2 days (Lobastova et al. 2004):



CCXLVI


N-Methylcarbazole (**CCXLVII**) is biotransformed by *Cunninghamella echinulata* to carbazole, *N*-hydroxymethylcarbazole (**CCXLVIII**), 3-hydroxycarbazole, and 3-hydroxy-*N*-hydroxymethylcarbazole (**CCXLIX**) (Yang and Davis 1992):



CCXLVII




CCXLVIII




CCXLIX

The transformation of *N*-benzoylcarbazole (**CCL**) and *N*-acetylcarbazole (**CCLI**) by *A. flavus* forms carbazole as the main product and small quantities of 1-, 2-, and 3-hydroxycarbazoles (Lobastova et al. 2004):



CCL




CCLI


Beta-carbolines

The metabolism of ethyl- β -carboline-3-carboxylates (**CCLII**) by cultures of bacteria and fungi has been investigated (Neef et al. 1982). The bacteria *Streptomyces lavendulae* and *S. griseus* hydroxylated the 4-ethyl and 4-*n*-propyl derivatives of ethyl- β -carboline-3-carboxylate (**CCLII** with R = C₂H₅ or C₃H₇), producing the corresponding lactones (**CCLIII** and **CCLIV**) by


transesterification. The yields in these processes were 7-8% (Neef et al. 1982):



CCLII, R= C₂H₅; C₃H₇




CCLIII




CCLIV

Beauveria bassiana hydroxylates the same compounds, usually forming a mixture of glucosides. Only in the case of 4-unsubstituted β-carboline-3-carboxylate (**CLXVIII**, R=H) has the non-glucosylated 6-hydroxy derivative (**CCLV**, yield 62%) been found. If there is an alkyl substituent in **CCLII** in position 4, then the 6- and 8-(4'-O-methyl)-β-glucosides (**CCLVI** and **CCLVII**, respectively), are produced. An increase in chain length of the alkyl substituent leads to an increase in the amount of the 8-glucoside (Neef et al. 1982):



CCLV, R=H


CCLVI, R=CH₃; C₂H₅; C₃H₇




CCLVII, R=CH₃; C₂H₅; C₃H₇

Gamma-carbolines


Penicillium simplicissimum transforms the antihistamine 2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-pyrido[4,3-*b*]indole (latrepirdine or Dimebon, **CCLVIII**) with the formation of a 2,3-dehydro derivative (**CCLIX**) and a 4-acetyl, 5-carbonyl, 2,3-dehydro derivative (**CCLX**) in 10.0% yields (Dovgilevich et al. 1991):



CCLVIII



CCLIX



CCLX

The 4-acetyl, 5-carbonyl, 2,3-dehydro derivative may be formed by 4*N*-demethylation and 5-position oxidation of the 2,3-dehydro derivative, followed by acetylation of the nitrogen at position 4 of the γ -carboline ring (Dovgilevich et al. 1991).

Chapter 3. Microbial transformations of quinolones and related drugs


Because quinolones are widely used in medical and veterinary practices as well as in animal production and aquaculture in many countries (Martinsen and Horsberg, 1995; Andriole, 2000), and the problem of quinolone resistance among pathogenic bacteria remains serious (Cattoir and Nordmann, 2009), it will require the development of new antimicrobial agents.

It is likely that modification of the chemical structure of quinolones can help to solve these problems (Murphy et al., 2009). In addition, new quinolone derivatives obtained by the methods of regio- and stereospecific microbial biotransformation (Lehman and Stewart, 2001) combined with chemical synthesis may be useful in the synthesis of new generations of quinolones.


3.1. Transformations of first-generation quinolones and their analogs

Nalidixic acid (**CCLXI**), a derivative of 1,8-naphthyridine, inhibits DNA gyrase in bacteria (Sugino et al., 1977). It is usually considered the first of the quinolone-related compounds to be investigated as an antibacterial agent, even though it is, strictly speaking, not a quinolone (Lesher et al., 1962). Nalidixic acid has been used against urinary tract infections caused by Gram-negative bacteria (Sabbour et al., 1984) and it also has antimalarial properties (Divo et al., 1988; Mahmoudi et al., 2003).


The transformation of nalidixic acid by the fungus *Penicillium adametzi* 737 has been studied (Hamilton et al., 1969). After 24 hours, the formation of a hydroxymethyl derivative (**CCLXII**) was observed with a yield reaching 60%. Its further oxidation led to the formation of a 3,7-dicarboxylic acid (**CCLXIII**) (Hamilton et al., 1969):



CCLXI




CCLXII




CCLXIII

The microbial transformation of analogues of nalidixic acid has also been of great interest. In a growing culture of *P. adametzi* ATCC 10407, oxidation of the methyl group of 3-carboxy-1-ethyl-7-methyl-4-quinolone (**CCLXIV**) to the alcohol, 3-carboxy-1-ethyl-7-hydroxymethyl-4-quinolone (**CCLXV**), was observed; the aromatic carbon atoms were not involved in this process (Kieslich et al., 1973):




CCLXIV




CCLXV

From the same substrate, the bacterium *Streptomyces surinam* formed an *O*-acetylated derivative at the carboxyl group instead. *P. adametzi* also metabolized a similar compound with a methoxyl group by demethylating it (Kieslich et al., 1973).

A similar pattern is observed in the oxidation of a more complicated quinolone with an additional saturated ring, 1-ethyl-4-oxo-1,4,6,7,8,9-hexahydrobenzo[*g*]quinoline-3-carboxylic acid (**CCLXVI**), by three different microorganisms (Kieslich et al., 1973). The fungus *Beauveria bassiana* ATCC 7159 introduced a hydroxyl group at position 6, forming the 6-hydroxy derivative (**CCLXVII**); *P. adametzi* formed the 7- and 8-hydroxy derivatives (**CCLXVIII** and **CCLXIX**); and *Streptomyces achromogenes* formed the 6-, 7-, and 8-hydroxy derivatives (**CCLXVII**, **CCLXVIII** and **CCLXIX**) (Kieslich et al., 1973):




CCLXVI



CCLXVII





CCLXVIII




CCLXIX

Some analogs of acronycine (**CCLXX**), a pyranoacridone alkaloid, have antitumor activity (Nguyen et al., 2009) and antimalarial activity (Fujioka et al., 1989; 1990; Basco et al., 1994; Hari et al., 2010). The oxidation of acronycine by growing cultures of fungi in the genus *Cunninghamella* results in hydroxylation of the benzene ring (Betts et al., 1974). The most active strain, *C. echinulata* NRRL 3665, transformed the starting material into 9-hydroxyacronycine (**CCLXXI**) with a yield of 30% in 70 hours (Betts et al., 1974):




The transformation of cinoxacin (**CCLXXII**), a 4-cinnolone derivative that has been used for treating bacterial urinary tract infections [Sisca et al., 1983; Sabbour et al., 1984], was studied with *B. bassiana* ATCC 7159. Within 20 days, formation of two metabolites, 1-ethyl-1,4-dihydro-3-(hydroxymethyl)[1,3]dioxolo[4,5-g]cinnolin-4-one (**CCLXXIII**, yield 47.3%) and 1-ethyl-1,4-dihydro-6,7-dihydroxy-3-(hydroxymethyl)cinnolin-4-one (**CCLXXIV**, yield 5.6%), was observed (Parshikov et al., 2002a,b,c):




CCLXXII

CCLXXIII




CCLXXIV


Flumequine (**CCLXXV**) is a quinolone derivative, produced as a racemic mixture, that is used in aquaculture in many countries as an antibacterial agent (Martinsen and Horsberg, 1995; Rigos and Troisi, 2005; Kim and Cerniglia, 2010). In the stereospecific transformation of the flumequine isomers by growing cultures of *Cunninghamella elegans*, the formation of two diastereomers, 7-hydroxyflumequine (**CCLXXVI**, yield 23%, and **CCLXXVII**, yield 43%) and also 7-oxoflumequine (**CCLXXVIII**, 11% yield) was observed within 7 days (Williams et al., 2007):




CCLXXV



CCLXXVI



CCLXXVII




CCLXXVIII

3.2. Transformation of second-generation quinolones


The emergence of norfloxacin (**CCLXXIX**) as an antibacterial agent marked the beginning of the second generation of quinolones (Appelbaum and Hunter, 2000; Brighty and Gootz, 2000). It is still used for treatment of urinary tract infections [Sabbour et al., 1984] and conjunctivitis (Miller et al., 1992); laboratory tests have shown that it also possesses antimalarial activity (Sarma, 1989; Mahmoudi et al., 2003).

During the transformation of norfloxacin by the fungus *Pestalotiopsis guepini* P-8, four metabolites, *N*-acetylnorfloxacin (**CCLXXX**, yield 55.4%), desethylene *N*-acetylnorfloxacin (**CCLXXXI**, yield 8.8%), *N*-formylnorfloxacin (**CCLXXXII**, yield 3.6 %) and 7-amino-1-ethyl-6-fluoro-4-oxo-1,4-


dihydroquinoline-3-carboxylic acid (**CCLXXXIII**, yield 2.1%), were obtained (Parshikov et al., 2001a; Williams et al., 2004), all of which are known from human and animal studies (Dalhoff and Bergan 1998; Pauliukonis et al., 1984):




CCLXXIX, R=C₂H₅
CCLXXXV, R=C₃H₅



CCLXXX, R=C₂H₅
CCLXXXVI, R=C₃H₅




CCLXXXI, R=C₂H₅
CCLXXXVII, R=C₃H₅



CCLXXXII, R=C₂H₅
CCLXXXVIII, R=C₃H₅



CCLXXXIII, R=C₂H₅
CCLXXXIX, R=C₃H₅




CCLXXXIV, R=C₂H₅
CCXC, R=C₃H₅

In an attempt to identify biotransformation products and the enzymes involved in their formation, a wood-decaying white-rot basidiomycete, *Trametes versicolor*, was grown in a medium containing norfloxacin (Prieto et al., 2011). It produced desethylene N-acetylnorfloxacin and 7-amino-1-ethyl-6-fluoro-4-



oxo-1,4-dihydroquinoline-3-carboxylic acid from norfloxacin, plus desethylene norfloxacin (**CCLXXXIV**) (Prieto et al., 2011).

Although these products have not been specifically tested, they most likely have less antibacterial activity than norfloxacin or none at all (Dalhoff and Bergan 1998).


The fungus *Trichoderma viride*, when grown in the presence of norfloxacin and ciprofloxacin for 16 days, formed two conjugates (**CCXCI** and **CCXCII**) with yields of 42% and 31%. They were formed by the reaction of norfloxacin with a secondary metabolite of the fungus (Parshikov et al., 2000a; Parshikov et al., 2002):



Norfloxacin was also transformed by growing cultures of *Microbacterium* sp. 4N2-2 within 14 days to four metabolites: *N*-acetylnorfloxacin, desethylene-*N*-acetylnorfloxacin, 8-hydroxynorfloxacin (**CCXCIII**), and 6-hydroxynorfloxacin (**CCXCV**) (Kim et al., 2011):



Transformation of norfloxacin by growing cultures of an environmental isolate, *Mycobacterium gilvum* PYR-GCK, led to the formation not only of the inactive *N*-acetylnorfloxacin but also of *N*-nitrosonorfloxacin (**CCXCVII**) (Adjei et al., 2006):



The *N*-acetylation of norfloxacin by cultures of an *Escherichia coli* strain from wastewater with the variant gene *aac(6')-Ib-cr* has also been observed (Jung et al., 2009).

The fluoroquinolone ciprofloxacin (**CCLXXXV**) has a broad spectrum of activity and is widely prescribed for diseases caused by many bacteria (Sharma et al., 2010). It shows antimarial activity in vitro against chloroquine-sensitive strains of *Plasmodium falciparum*, but it was tested unsuccessfully for


treating patients with chloroquine-resistant malaria (Divo et al., 1988; Watt et al., 1991). Ciprofloxacin is able to interrupt the cell cycle of tumor cell lines (Kloskowski et al., 2010).

During the oxidation of ciprofloxacin by the wood-decaying brown-rot fungus *Gloeophyllum striatum*, the metabolites 8-hydroxyciprofloxacin (**CCXCIV**) and 6-hydroxyciprofloxacin (**CCXCVI**) were detected [Wetzstein et al., 1999].

The transformation of ciprofloxacin by growing cultures of the fungus *Umbelopsis ramanniana* (= *Mucor ramannianus*) produces one inactive metabolite, *N*-acetylciprofloxacin (**CCLXXXV**), with a yield of 89.0% (Parshikov et al., 1999). The transformation of ciprofloxacin by *P. guepini* P-8 produces four metabolites: *N*-acetylciprofloxacin (**CCLXXXV**, yield 52.0%), desethylene-*N*-acetylciprofloxacin (**CCLXXXVI**, yield 9.2%), *N*-formylciprofloxacin (**CCLXXXVII**, yield 4.2%) and 7-amino-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**CCLXXXVIII**, yield 2.3%) (Parshikov et al., 2001a,c).

The *N*-acetylation of ciprofloxacin by growing cultures of *E. coli* that have *aac(6')-Ib-cr* has been observed [Robicsek et al., 2006; Jung et al., 2009]. Transformation of ciprofloxacin by growing cultures of *M. gilvum* leads to the formation not only of *N*-acetylciprofloxacin (**CCLXXXV**) but also of *N*-nitrosociprofloxacin (**CCXCVIII**) (Adjei et al., 2007).

The basidiomycete *T. versicolor* transforms ciprofloxacin to 7-amino-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**CCLXXXIX**), desethylene ciprofloxacin (**CCXC**) and 8-hydroxyciprofloxacin (**CCXCIV**), which are also produced by *G. striatum*; three novel metabolites of *T. versicolor* are desethylene N-acetyl-8-hydroxyciprofloxacin (**CCXCIX**) and two unusual conjugates (**CCC** and **CCCI**) (Prieto et al., 2011):



3.3. Transformation of third-generation quinolones


To date, the most-studied microbial transformations of third-generation quinolones are those of the veterinary antibiotics enrofloxacin (Sellyei et al., 2009), saraflloxacin (Edens et al., 1997; Amjad et al., 2006; Abd El-Ghany et al., 2011), danofloxacin (Sappal et al., 2009) and pradofloxacin (Wetzstein et al., 2005).

Enrofloxacin (**CCCII**) is a veterinary antibacterial fluoroquinolone that is used for a great variety of purposes


(Martinsen and Horsberg, 1995; Mitchell, 2006; Sellyei et al., 2009). It is degraded completely to CO₂ by brown-rot fungi from decaying wood and agricultural soils (Martens et al., 1996; Wetzstein, 2001; 2010). The brown-rot fungi produce hydroxyl radicals by nonenzymatic processes (Arantes et al., 2012), and these appear to be involved in the biotransformation. A total of 137 metabolites, including CO₂, produced by basidiomycetous fungi from enrofloxacin were identified in a series of brilliant investigations using high-performance liquid chromatography and high-resolution mass spectrometry (Wetzstein et al., 1997; 2006; Karl et al., 2006). During the transformation of enrofloxacin by *G. striatum* DSM 9592, 87 metabolites were detected and identified (Karl et al., 2006); additional metabolites were found in cultures of seven other fungi (Wetzstein et al., 2006). Some of the metabolites were *O*-acetylated or *N*-oxidized and others were produced by cleavage of the pyridone ring. Because of the abundance of metabolites produced from enrofloxacin alone, the reader is referred to the original papers (Karl et al., 2006; Wetzstein et al., 2006) for the structures.

As a result of transformation of enrofloxacin by *U. ramanniana*, a non-wood-decaying zygomycetous fungus, three products, desethylene enrofloxacin (CCCIII, yield 3.5%), enrofloxacin *N*-oxide (CCCIIV, yield 62.0%) and *N*-


acetyl ciprofloxacin (**CCLXXXVI**, yield 8.0%), were produced within 21 days (Parshikov et al., 2000b,d):




Sarafloxacin (**CCCV**) has been used as an antibacterial agent in poultry production (Jones et al., 1998; Abd El-Ghany et al., 2011) and in aquaculture (Martinsen and Horsberg, 1995; Kim and Cerniglia, 2010). The transformation of sarafloxacin was studied with growing cultures of *U. ramanniana*. Within 18 days, the formation of two metabolites, desethylene-*N*-acetylsarafloxacin (**CCCVI**, yield 26.0%) and *N*-acetylsarafloxacin (**CCCVII**, yield 15.0%), was observed (Parshikov et al., 2000c; Parshikov et al., 2001b):



CCCV




CCCVI



CCCVII


Danofloxacin (CCCVIII) is used for treating bacterial infections of cattle, pigs, and other livestock (McGuirk et al., 1992; Sappal et al., 2009). The transformation of danofloxacin by cultures of the bacteria *Mycobacterium smegmatis* UI AM-563 and *Pseudomonas fluorescens* UI AM-670 produces two metabolites, *N*-desmethyldanofloxacin (CCCIIX) and a 7-amino derivative (CCLXXXIX) (Chen et al., 1997):




CCCVIII

CCCIX


Pradofloxacin (**CCCX**) is a veterinary fluoroquinolone, with a cyano group on position 8, which was developed for treating bacterial infections in dogs and cats (Wetzstein, 2005). Transformation of pradofloxacin by *G. striatum* DSM 9592 produced six major metabolites, probably by hydroxyl radical reactions. The major metabolites were 2-hydroxy-8-cyanopradoфloxacin (**CCCXI**, yield 3.0%), 6-hydroxy-8-cyanopradoфloxacin (**CCCXII**, yield 9.0%), 5,6-dihydroxy-8-cyanopradoфloxacin (**CCCXIII**, yield 3.0%), 8-hydroxypradoфloxacin (**CCCXIV**, yield 1.0%), 8-cyano-7-amino pradofloxacin (**CCCXV**, 1.0% yield) and 6-[(E/Z)-1-cyano-2-hydroxyethenyl]-1-cyclopropyl-4-oxo-1,4-dihydro-3-pyridinecarboxylic acid (**CCCXVI**, yield 1.0%) in 16 days (Wetzstein et al., 2012):




CCCX




CCCXI




CCCXII




CCCXIII



CCCXIV



CCCXV




CCCXVI


At least the 8-hydroxypradofloxacin metabolite lacks antimicrobial activity (Wetzstein and Hallenbach, 2011). The unique feature of this fungal biotransformation occurs after the pyrrolodinopiperidine group at position 7 is removed, when the carbocyclic ring is cleaved (Wetzstein et al., 2012). Cleavage of this aromatic ring has been suspected in the fungal transformation of other drugs but has previously not been confirmed.

3.4. Transformation of fourth-generation quinolones


There is little information in the literature about the microbial transformations of fourth-generation quinolones except for moxifloxacin (**CCCXVII**), an 8-methoxyfluoroquinolone (BAY 12-8039) used for treating infections of the skin and respiratory tract (Keating and Scott, 2004). In the biotransformation of moxifloxacin by *G. striatum* DSM 9592, several metabolites, among them 3-hydroxymoxifloxacin (**CCCXVIII**), 6-hydroxymoxifloxacin (**CCCXIX**), and a demethylated derivative (8-hydroxymoxifloxacin) (**CCCXXX**), were produced in 3 days (Wetzstein et al., 1997):




CCCXVII



CCCXVIII



CCCXIX



CCCXX

Conclusion

On the basis of compounds of a series azaarenes exist many types of medications. Derivatives of quinoline wide known among the most promising drugs. Primaquine has many side effects, so research is underway to develop an effective and safe antimalarial drug based on it (Vale et al., 2009).

Quinolones are widely used in medical practice. However, the problem of occurrence of antibiotic resistant strains of pathogenic microorganisms remains unchanged. Modification of the chemical structure of quinolones can solve these issues. Derivatives obtained by the methods of microbial chemistry may prove useful in the synthesis of a new generation of quinolones.

Hydroxylated derivatives of saturated nitrogen-containing heterocycles obtained by microbial techniques may be used to create hybrid molecules based, artemisinin (Parshikov et al., 2004a,b,c, 2005, 2006; Williamson et al., 2007), quinine and chloroquine.

References

Abd El-Ghany W.A., Madian K. Control of experimental colisepticaemia in broiler chickens using sarafloxacin. Life Sci. J. 2011. V. 8. N 3. P.318-328.

Achan J., Talisuna A.O., Erhart A., Yeka A., Tibenderana J.K., Baliraine F.N., Rosenthal P.J., D'Alessandro U. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malaria J. 2011. V. 10. N 144, P.12.

Adjei M.D., Heinze T.M., Deck J., Freeman J.P., Williams A.J., Sutherland J.B. Transformation of the antibacterial agent norfloxacin by environmental mycobacteria. Appl. Environ. Microbiol. 2006. V. 72. N 9. P.5790-5793.

Adjei M.D., Heinze T.M., Deck J., Freeman J.P., Williams. A.J., Sutherland J.B. Acetylation and nitrosation of ciprofloxacin by environmental strains of mycobacteria. Can. J. Microbiol. 2007. V. 53. P.144-147.

Agarwal A., Srivastava K., Puri S.K., Chauhan P.M.S. Synthesis of substituted indole derivatives as a new class of antimalarial agents. Bioorg. Med. Chem. Lett. 2005. V. 15. P. 3133–3136.

Ahmad S., Henderson K., Dunsday G., Zachariou M. Microbial biotransformations: stereoselective synthesis of

pharmaceutical drug precursors. *Australas Biotechnol.* 2001. N 11. P.26–28.

Ahn K.H., Shin Y-S. Synthesis of 1,4-dideoxy-1,4-imino-D-arabinitol (D-AB-1) through a divergent approach. *Bull. Korean Chem. Soc.* 1997. V. 18. N 11. P.1192-1195.

Aislabie J., Bej A.K., Hurst H., Rothenburger S., Atlas R.M. Microbial degradation of quinoline and methylquinolines. *Appl. Environ. Microbiol.* 1990. N 56. P.345–351.

Aislabie J., Rothenburger S., Atlas R.M. Isolation of microorganisms capable of degrading isoquinoline under aerobic conditions. *Appl. Environ. Microbiol.* 1989. V. 55. P.3247–3249.

Amjad H., Iqbal J., Naeem M. Estimation of selected residual antibiotics in muscle, kidney, liver and egg of layer chicken. *Proc. Pakistan Acad. Sci.* 2006. V. 43. N 1. P.29-37.

Andersson M.I., MacGowan A.P. Development of the quinolones. *J. Antimicrob. Chemother.* 2003. V. 51. Suppl. S1. P.1-11

Andries K., Verhasselt P., Guillemont J., Göhlmann H.W.H, Neefs J-M., Winkler H., Van Gestel J., Timmerman P., Zhu M., Lee E., Williams P., de Chaffoy D., Huitric E., Hoffner S., Cambau E., Truffot-Pernot C., Lounis N., Jarlier V. A diarylquinoline drug active on the ATP synthase of *Mycobacterium tuberculosis*. *Science.* 2005. V. 307. P.223–227.

Andriole V.T. The quinolones: prospects. In: The Quinolones. - 3rd ed. (Andriole V.T., ed.) San Diego: Academic Press, 2000. C.477–95.

Appelbaum PC, Hunter PA. The fluoroquinolone antibiotics: past, present and future perspectives. Int. J. Antimicrob. Agents. 2000. V. 16. P.5-15.

Arantes V., Jellison J, Goodell G. Peculiarities of brown-rot fungi and biochemical Fenton reaction with regard to their potential as a model for bioprocessing biomass. Appl. Microbiol. Biotechnol. 2012. 94: 323-338.

Araújo N.C.P., Barton V., Jones M., Stocks P.A., Ward S.A., Davies J., Bray P.G., Shone A.E., Cristiano M.L.S., O'Neill P.M. Semi-synthetic and synthetic 1,2,4-trioxaquines and 1,2,4-trioxolaquines: synthesis, preliminary SAR and comparison with acridine endoperoxide conjugates. Bioorg Med Chem Lett, 2009. 19:2038–2043

Archelas A., Furneron I.D., Furstoss R. Microbial transformations 11. Regioselective hydroxylation of β -lactams by the fungus *Beauveria sulfurescens*. Tetrahedron Lett. 1988. 29(50):6611-6613. doi: 10.1016/S0040-4039(00)82410-7

Archelas A., Furstoss R., Srairi D., Maurey G. Transformations microbiologiques, 5. Hydroxylation microbiologique de lactames, d'amides et d'imides monocycliques

par le champignon *Beauveria sulfurescens*. Bull Soc Chim Fr. 1986. 2:234-238.

Auparakkitanon S, Noonpakdee W, Ralph RK, Denny WA, Wilairat P. Antimalarial 9-anilinoacridine compounds directed at hematin. *Antimicrob Agents Chemother*. 2003. 47:3708–3712.

Aurrecoechea JM, Bustos F, López B, Saornil C, Suero R. A new entry into 3-hydroxypyrrolidine derivatives from protected α- or β-amino esters. *Arkivoc*. 2009. 11:94-104.

Baird J.K. Resistance to chloroquine unhinges vivax malaria therapeutics. *Antimicrob. Agents. Chemother*. 2011. 55:1827–1830.

Baker P. Biotransformations. *Lab Pract*. 1987. 36(7):46-47.

Ball P. Quinolone generations: natural history or natural selection? *J. Antimicrob. Chemother*. 2000a. V. 46 Suppl. T1. P.17-24.

Ball P. The quinolones: history and overview. In: *The Quinolones*, 3rd ed. (Andriole V.T., ed.) San Diego: Academic Press, 2000. p. 1-31.

Banasik M, Komura H, Shimoyama M, Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. *J Biol Chem*. 1992. 267:1569–1575.

Barreiros L, Fernandes A, Ferreira ACS, Pereira H, Bastos MMSM, Manaia CM, Nunes OC. New insights into a bacterial

metabolic and detoxifying association responsible for the mineralization of the thiocarbamate herbicide molinate.

Microbiology. 2008. 154:1038-1046. doi:
10.1099/mic.0.2007/015297-0

Basco L.K., Mitaku S., Skaltsounis A.-L.,
Ravelomanantsoa N., Tillequin F., Koch M., LeBras J. *In vitro*
activities of furoquinoline and acridone alkaloids against
Plasmodium falciparum. Antimicrob. Agents Chemother. 1994. V.
38. N 5. P.1169-1171.

Bertrand L, Kremsner PG Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother. 2002. 46(8):2315-2320. doi: 10.1128/AAC.46.8.2315-2320.2002

Betts R.E., Walters D.E., Rosazza J. Microbial transformations of antitumor compounds. 1. Conversion of acronycine to 9-hydroxyacronycine by *Cunninghamella echinulata*. J. Med. Chem. 1974. V. 17. N 6. P.599-602.

Bianchi D, Bosetti A, Cidaria D, Bernardi A, Gagliardi I, D'Amico P (1997) Oxidation of polycyclic aromatic heterocycles by *Pseudomonas fluorescens* TTC1. Appl Microbiol Biotechnol 47:596–599

Boaventura MAD, Lopes RFAP, Takahashi JA (2004)
Microorganisms as tools in modern chemistry: the

biotransformation of 3-indolylacetonitrile and tryptamine by fungi.
Braz J Microbiol 35:345–347

Boibessot I, Turner CMR, Watson DG, Goldie E, Connell G, McIntosh A, Grant MH, Skellern GG (2002) Metabolism and distribution of phenanthridine trypanocides in *Trypanosoma brucei*. Acta Tropica 84:219–228

Bot C, Hall BS, Bashir N, Taylor MC, Helsby NA, Wilkinson SR (2010) Trypanocidal activity of aziridinyl nitrobenzamide prodrugs. Antimicrob. Agents Chemother. 54(10):4246-4252. doi: 10.1128/AAC.00800-10

Boteva A. A., Krasnykh O. P. The methods of synthesis, modification, and biological activity of 4-quinolones (review). Chem. Heterocycl. Compds. 2009. V. 45. N 7. P. 757-785.

Bott G, Lingens F (1991) Microbial metabolism of quinoline and related compounds. IX. Degradation of 6-hydroxyquinoline and quinoline by *Pseudomonas diminuta* 31/1 Fa1 and *Bacillus circulans* 31/2 A1. Biol Chem Hoppe-Seyler 372:381–383

Boyd DR, McMordie RAS, Porter HP, Dalton H, Jenkins RO, Howarth OW (1987) Metabolism of bicyclic aza-arenes by *Pseudomonas putida* to yield vicinal *cis*-dihydrodiols and phenols. J Chem Soc Chem Commun 1987:1722–1724

Boyd DR, Sharma ND, Dorrity MRJ, Hand MV,
McMordie RAS, Malone JF, Porter HP, Dalton H, Chima J,
Sheldrake GN (1993) Structure and stereochemistry of *cis*-dihydro
diol and phenol metabolites of bicyclic azaarenes from
Pseudomonas putida UV4. J Chem Soc Perkin Trans 1
1993:1065–1071

Boyd DR, Sharma ND, Modyanova LV, Carroll JG,
Malone JF, Allen CCR, Hamilton JT, Gibson DT, Parales RE,
Dalton H (2002) Dioxygenase-catalyzed *cis*-dihydroxylation of
pyridine-ring systems. Can J Chem 80:589–600

Bressler DC, Fedorak PM (2000) Bacterial metabolism of
fluorene, dibenzofuran, dibenzothiophene, and carbazole. Can J
Microbiol 46:397–409

Brighty K.E., Gootz T.D. Chemistry and mechanism of
action of the quinolone antibacterials. In: The Quinolones. 3rd ed.
(Andriole V.T., ed.) San Diego: Academic Press, 2000. P.33–97.

Brocks DR, Mehvar R (2003) Stereoselectivity in the
pharmacodynamics and pharmacokinetics of the chiral
antimalarial drugs. Clin Pharmacokinet 42:1359–1382

Cattoir V, Nordmann P. Plasmid-mediated quinolone
resistance in Gram-negative bacterial species: an update. Curr.
Med. Chem. 2009. 16: 1028-1046.

Chang D, Feiten H-J, Engesser KH, Van Beilen JB, Witholt B, Li Z (2002) Practical syntheses of *N*-substituted 3-hydroxyazetidines and 4-hydroxypiperidines by hydroxylation with *Sphingomonas* sp. HXN-200. *Org Lett.* 4(11):1859-1862. doi: 10.1021/o1025829s

Chauhan SS, Sharma M, Chauhan PMS (2010) Trioxaquines: hybrid molecules for the treatment of malaria. *Drug News Perspect* 23:632–646

Chawla R, Singh AK, Yadav LDS (2013) Organocatalysis in synthesis and reactions of epoxides and aziridines. *RSC Advances.* 3(29):11385-11403. doi: 10.1039/C3RA00175J

Chen P, Gao M, Wang DX, Zhao L, Wang MX (2012) Enantioselective biotransformations of racemic and meso pyrrolidine-2,5-dicarboxamides and their application in organic synthesis. *J Org Chem.* 77:4063-4072. doi: 10.1021/jo300412j

Chen Y., Rosazza J.P.N., Reese C.P., Chang H.-Y., Nowakowski M.A., Kiplinger J.P. Microbial models of soil metabolism: biotransformations of danofloxacin. *J. Ind. Microbiol. Biotechnol.* 1997. V. 19. P.378–384.

Clark AM, Hufford CD, Gupta RC, Puri RK, McChesney JD (1984a) Microbial transformation of primaquine by *Candida tropicalis*. *Appl Environ Microbiol* 47:537–539.

Clark AM, Hufford CD, Puri RK, McChesney JD (1984b) Production of a novel dimeric metabolite of primaquine by *Streptomyces rimosus*. Appl Environ Microbiol 47:540–543.

Coslédan F, Fraisse L, Pellet A, Guillou F, Mordmüller B, Kremsner PG, Moreno A, Mazier D, Maffrand J-P, Meunier B (2008) Selection of a trioxaquine as an antimalarial drug candidate. Proc Nat Acad Sci USA 105:17579–17584.

Cui M, Chen F, Fu J, Sheng G, Sun G (2004) Microbial metabolism of quinoline by *Comamonas* sp. World J Microbiol Biotechnol 20:539–543.

Dalhoff A, Schmitz F-J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 2003. 22: 203-221.

Deretic V, Pagán-Ramos E, Zhang Y, Dhandayuthapani S, Via LE (1996) The extreme sensitivity of *Mycobacterium tuberculosis* to the front-line antituberculosis drug isoniazid. Nature Biotechnol 14:1557–1561.

Dexian W, Meixiang W (2010) Biotransformations of three-membered (hetero) cyclic nitriles and their applications in organic synthesis. Progress in Chemistry. 22(7):1397-1402.

D'hooghe M, Kenis S, Vervisch K, Lategan C, Smith PJ, Chibale K, De Kimpe N (2011) Synthesis of 2-(aminomethyl)aziridines and their microwave-assisted ring

opening to 1,2,3-triaminopropanes as novel antimalarial pharmacophores. Eur J Med Chem. 46(2):579–587. doi: 10.1016/j.ejmech.2010.11.037

Diethelm S, Carreira EM (2013) Total Synthesis of (\pm)-Gelsemoxonine. J Am Chem Soc. 135(23):8500-8503. doi: 10.1021/ja208617c

Divo A.A., Sartorelli A.C., Patton C.L., Bia F.J. Activity of fluoroquinolone antibiotics against *Plasmodium falciparum* *in vitro*. Antimicrob. Agents Chemother. 1988. V. 32. N 8. P.1182-1186.

Dovgilevich E.V., Parshikov I.A., Modyanova L.V., Terent'ev P.B., Bulakhov G.A. A novel microbial transformation of γ -carboline derivative 3,6-dimethyl-9-[2-(2-methylpyrid-5-yl)ethyl]-1,2,3,4-tetrahydro- γ -carboline. Mendeleev Communications. 1991. 1:42–43

Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 1997. 61: 377-392.

Duran N, De Conti R, Rodrigues JAR (2000) Biotransformations by microorganisms, organisms and enzymes: state of art. Bol Soc Chil Quim. 45(1):109-121

Duran N, De Conti R, Rodrigues JAR (2000) Biotransformations by microorganisms, organisms and enzymes: state of art. Bol Soc Chil Quím 45:109–121.

Edens F. W., Qureshi R. A., Parkhurst C. R., Qureshi M. A., Havenstein G. B., Casas I. A. Characterization of two *Escherichia coli* isolates associated with poult enteritis and mortality syndrome. Poult. Sci. 1997. V. 76. P.1665–1673.

Ensley BD, Ratzkin BJ, Osslund TD, Simon MJ, Wackett LP, Gibson DT (1983) Expression of naphthalene oxidation genes in *Escherichia coli* results in the biosynthesis of indigo. Science 222:167–169.

Faber K (2004) Biotransformations in Organic Chemistry. Springer, Heidelberg. 321P.

Faber K (2011) Biotransformations in Organic Chemistry: A Textbook, 6th ed. Springer, Berlin. 434 p.

Fattorusso E, Taglialatela-Scafati O (2009) Marine Antimalarials. Mar Drugs. 7:130-152. doi: 10.3390/md7020130

Fetzner S (1998) Bacterial degradation of pyridine, indole, quinoline, and their derivatives under different redox conditions. Appl Microbiol Biotechnol 49:237–250.

Fetzner S, Tshisuaka B, Lingens F, Kappl R, Hüttermann J (1998) Bacterial degradation of quinoline and derivatives—pathways and their biocatalysts. Angew Chem Int Ed 37:576–597.

Feula A, Male L, Fossey JS (2010) Diastereoselective preparation of azetidines and pyrrolidines. Org Lett. 12(21):5044–5047. doi: 10.1021/o102215e

Fujioka H., Nishiyama Y., Furukawa H., Kumada N. *In vitro* and *in vivo* activities of atalaphillinine and related acridone alkaloids against rodent malaria. // Antimicrob. Agents Chemother. 1989. V. 33. P.6-9.

Fujioka, H., Kato N., Fujita M., Fujimura K., Nishiyama Y. Activities of new acridone alkaloid derivatives against *Plasmodium yoelii* *in vitro*. Arzneim.-Forsch./Drug Res. 1990. V. 40. P.1026-1029.

Fürmeier S, Metzger JO (2003) Fat-Derived aziridines and their *N*-substituted derivatives: biologically active compounds based on renewable raw materials. Eur J Org Chem. 4:649-659.
doi: 10.1002/ejoc.200390105

Gatti D., Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging. 1999. 15:285–296.

Ge J-F, Arai C, Yang M, Md AB, Lu J, Ismail NSM, Wittlin S, Kaiser M, Brun R, Charman SA, Nguyen T, Morizzi J, Itoh I, Ihara M (2010) Discovery of novel benzo[*a*]phenoxyazine SSJ-183 as a drug candidate for malaria. ACS Med Chem Lett 1:360–364.

Georg GI, Guan X (1992) Asymmetric synthesis of α -alkylated α -amino acids: azocane-2-carboxylic acids. Tetrahedron Lett. 33:17-20. doi: 10.1016/S0040-4039(00)77662-3

Ghorai MK, Das K, Kumar A (2007) A convenient synthetic route to enantiopure *N*-tosylazetidines from α -amino acids. *Tetrahedron Lett.* 48:2471–2475. doi: 10.1016/j.tetlet.2007.02.033

Gieg LM, Otter A, Fedorak PM (1996) Carbazole degradation by *Pseudomonas* sp. LD2: metabolic characteristics and the identification of some metabolites. *Environ Sci Technol* 30:575–585

Gomtsyan A, Bayburt EK, Schmidt RG, Zheng GZ, Perner RJ, Didomenico S, Koenig JR, Turner S, Jinkerson T, Drizin I, Hannick SM, Macri BS, McDonald HA, Honore P, Wismer CT, Marsh KC, Wetter J, Stewart KD, Oie T, Jarvis MF, Surowy CS, Faltynek CR, Lee C-H (2005) Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. *J Med Chem* 48:744–752

Grant DJW, Al-Najjar TR (1976) Degradation of quinoline by a soil bacterium. *Microbios* 15:177–189.

Grishina GV, Veselov IS, Nelyubina YV, Surovaya AN, Zefirov NS (2011) Optically pure trans-1-benzyl-4-aminopiperidin-3-ols. Synthesis and absolute configuration. *Arkivoc*. 10:107-117. doi: 10.3998/ark.5550190.0012.a09

Grogan GJ, Holland HL (2000) The biocatalytic reactions of *Beauveria* spp. J Mol Catal B Enzym 9:1–32.

Gross C, Felsheim R, Wackett LP (2008) Genes and enzymes of azetidine-2-carboxylate metabolism detoxification and assimilation of an antibiotic. J Bacteriol. 190(14):4859–4864. doi: 10.1128/JB.02022-07

Guetzoyan L, Yu X-M, Ramiandrasoa F, Pethe S, Rogier C, Pradines B, Cresteil T, Perrée-Fauvet M, Mahy J-P (2009) Antimalarial acridines: synthesis, in vitro activity against *P. falciparum* and interaction with hematin. Bioorg Med Chem 17:8032–8039.

Hamilton P.B., Rosi D., Peruzzotti G.P., Nielson E.D. Microbiological metabolism of naphthyridines. Appl. Microbiol. 1969. V. 17. N 2. P.237-241.

Hari G.S., Lee Y.R., Wang X., Lyoo W.S., Kim S.H. New synthetic routes to acronycine, noracronycine, and their analogues. Bull. Korean Chem. Soc. 2010. V. 31. N 8. P.2406-2409.

Hassner A (2009) Adventures in stereochemistry and cycloadditions. Bull Israel Chem Soc. 24:20-25

Hill JC, Johnson GT (1969) Microbial transformation of phenazines by *Aspergillus sclerotiorum*. Mycologia 61:452–467.

Hocart SJ, Liu H, Deng H, De D, Krogstad FM, Krogstad DJ (2011) 4-Aminoquinolines active against chloroquine-resistant

Plasmodium falciparum: basis of antiparasite activity and quantitative structure-activity relationship analyses. *Antimicrob Agents Chemother.* 55(5):2233-2244. doi: 10.1128/AAC.00675-10

Hodgson DM, Fleming MJ, Xu Z, Lin C, Stanway SJ (2006) 3-Hydroxypyrrolidines from epoxysulfonamides and dimethylsulfoxonium methylide. *Chem Commun.* 30:3226–3228. doi: 10.1039/B606583J

Hüttel W, Hoffmeister D (2010) Fungal biotransformations in pharmaceutical sciences. *The Mycota.* 10(3):293-317. doi: 10.1007/978-3-642-11458-8_14

Hüttel W, Hoffmeister D (2010) Fungal biotransformations in pharmaceutical sciences. In: Hofrichter M (ed), *The Mycota*, Vol. 10, Industrial Applications, Springer, Berlin, pp 293–317.

Inoue K, Habe H, Yamane H, Nojiri H (2006) Characterization of novel carbazole catabolism genes from Gram-positive carbazole degrader *Nocardoides aromaticivorans* IC177. *Appl Environ Microbiol* 72:3321–3329

Johansen SS, Licht D, Arvin E, Mosbaek H, Hansen AB (1997) Metabolic pathways of quinoline, indole and their methylated analogs by *Desulfobacterium indolicum* (DSM 3383). *Appl Microbiol Biotechnol* 47:292–300.

Johnson RA, Herr ME, Murray HC, Chidester CG, Han F (1992) Selective Oxygenation of Adamantanes and Other

Substrates by *Beauveria sulfurescens*. J Org Chem. 57(26): 7209-7212. doi: 10.1021/jo00052a039

Johnson RA, Herr ME, Murray HC, Fonken GS (1968a) The microbiological oxygenation of azacycloalkanes. Structural determinations leading to transannular reactions. J Org Chem. 33(8):3187-3195. doi: 10.1021/jo01272a035

Johnson RA, Herr ME, Murray HC, Reineke LM, Fonken, GS (1968b) The microbiological oxygenation of some azabicycloalkanes. J Org Chem. 33(8):3195-3201. doi: 10.1021/jo01272a036

Johnson RA, Murray HC, Reineke LM, Fonken GS (1969) Stereochemistry of microbiological hydroxylation. II. Oxygenation of 1-benzoylalkylpiperidines. J Org Chem. 34(8):2279-2284. doi: 10.1021/jo01260a009

Jones M, Mercer AE, Stocks PA, La Pensée LJ, Cosstick R, Park BK, Kennedy ME, Piantanida I, Ward SA, Davies J, Bray PG, Rawe SL, Baird J, Charidza T, Janneh O, O'Neill PM (2009) Antitumour and antimalarial activity of artemisinin-acridine hybrids. Bioorg Med Chem Lett 19:2033–2037

Jones RN, Erwin ME, et al. In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): a fluoroquinolone used for treatment and control of colibacillosis in poultry. Diagn. Microbiol. Infect. Dis. 1998. 32: 55-64.

Jung C.M., Heinze T.M., Strakosha R., Elkins C.A., Sutherland J.B. Acetylation of fluoroquinolone antimicrobial agents by an *Escherichia coli* strain isolated from a municipal wastewater treatment plant. *J. Appl. Microbiol.* 2009. V. 106. P.564-571.

Kaiser J-P, Feng Y, Bollag J-M (1996) Microbial metabolism of pyridine, quinoline, acridine, and their derivatives under aerobic and anaerobic conditions. *Microbiol Rev* 60:483–498

Kalkanidis M, Klonis N, Tilley L, Deady LW (2002) Novel phenothiazine antimalarials: synthesis, antimalarial activity, and inhibition of the formation of beta-haematin. *Biochem Pharmacol* 63:833–842

Kamath AV, Vaidyanathan CS (1990) New pathway for the biodegradation of indole in *Aspergillus niger*. *Appl Environ Microbiol* 56:275–280

Karl W, Schneider J, Wetzstein H-G. Outlines of an "exploding" network of metabolites generated from the fluoroquinolone enrofloxacin by the brown rot fungus *Gloeophyllum striatum*. *Appl. Microbiol. Biotechnol.* 2006. 71: 101-113.

Kaur K, Jain M, Kaur T, Jain R (2009) Antimalarials from nature. *Bioorg Med Chem* 17:3229–3256

Kaur K, Jain M, Reddy RP, Jain R (2010) Quinolines and structurally related heterocycles as antimalarials. Eur J Med Chem 45:3245–3264

Keating GM, Scott LJ. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 2004. 64: 2347-2377.

Keifer PA, Nagel DL, Cromwell NH (1988) Stereochemistry and bonding in *N*-substituted-2-phenyl-3-cyanoaziridines. J Heterocycl Chem. 25(2):353–359. doi: 10.1002/jhet.5570250201

Kelly SL, Lamb DC, Jackson CJ, Warrilow AGS, Kelly DE (2003) The biodiversity of microbial cytochromes P450. Adv Microb Physiol 47:131–186

Khasaeva F.M., Zakharchuk L.M., Netrusov A.I., Parshikov I.A. Biodegradation of pyridine by *Arthrobacter* sp. Natural Science. In: Young Scientist USA. 2014. V.1, P.50-52.

Kiener A. Enzymatic oxidation of methyl groups on aromatic heterocycles: a versatile method for the preparation of heteroaromatic carboxylic acids. Angew Chem Int Ed Engl. 1992. 31:774–775

Kieslich K., Wieglepp H., Hoyer G.-A., Rosenberg D. Mikrobiologische Umwandlungen nichtsteroider Strukturen. V. Mikrobiologische Reaktionen von substituierten 1-Äthyl-4-oxo-

1,4-dihydrochinolin-3-carbonsäuren. Chem. Ber. 1973. Bd. 106. N 8. P.2636-2642.

Kilbane JJ, Ranganathan R, Cleveland L, Kayser KJ, Ribiero C, Linhares MM (2000) Selective removal of nitrogen from quinoline and petroleum by *Pseudomonas ayucida* IGTN9m. Appl Environ Microbiol 66:688–693

Kim D.-W., Heinze T.M., Kim B.-S., Schnackenberg L.K., Woodling K.A., Sutherland J.B. Modification of norfloxacin by a *Microbacterium* sp. strain isolated from a wastewater treatment plant. Appl. Environ. Microbiol. 2011. V. 77. N 17. P.6100-6108.

Kim Y-H, Cerniglia CE. An overview of the fate and effects of antimicrobials used in aquaculture. In: Veterinary Pharmaceuticals in the Environment (Henderson KL, Coats JR, eds). 2010. Oxford University Press, New York.

King D.E., Malone R., Lilley S.H. New classification and update on the quinolone antibiotics. Am. Fam. Physician. 2000. V. 61. N 9. P.2741-2748.

Kłoskowski T, Gurtowska N, Drewa T. Does ciprofloxacin have an obverse and a reverse? Pulm. Pharmacol. Ther. 2010. 23: 373-375.

Kontnik R, Clardy J (2008) Codinaeopsin, an antimalarial fungal polyketide. Org Lett 10:4149–4151

Kost AN, Modyanova LV (1979) Microbiological transformation of pyridine derivatives. Khim Geterotsikl Soed 10:1299–1313

Kumar S, Das SK, Dey S, Maity P, Guha M, Choubey V, Panda G, Bandyopadhyay U (2008) Antiplasmodial activity of [(aryl)arylsulfanyl methyl]pyridine. Antimicrob Agents Chemother 52:705–715

Larentis AL, Sampaio HCC, Carneiro CC, Martins OB, Alves TLM (2011) Evaluation of growth, carbazole biodegradation and anthranilic acid production by *Pseudomonas stutzeri*. Braz J Chem Eng 28:37–44

Lee JJ, Yoon J-H, Yang S-Y, Lee S-T (2006) Aerobic biodegradation of 4-methylpyridine and 4-ethylpyridine by newly isolated *Pseudonocardia* sp. strain M43. FEMS Microbiol Lett 254:95–100

Lehman LR, Stewart JD (2001) Filamentous fungi: potentially useful catalysts for the biohydroxylations of non-activated carbon centers. Curr Org Chem 5:439–470

Lehman LR, Stewart JD. Filamentous fungi: potentially useful catalysts for the biohydroxylations of non-activated carbon centers. Curr. Org. Chem. 2001. 5: 439-470.

Leng DH, Wang DeX, Pan J, Huang ZT, Wang MX (2009) Highly efficient and enantioselective biotransformations of

racemic azetidine-2-carbonitriles and their synthetic applications. J Org Chem. 74:6077-6082. doi: 10.1021/jo9011656

Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP. 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Chem. 1962. 5: 1063-1065.

Li P, Tong L, Liu K, Wang Y, Wang Y (2009) Indole degrading of ammonia oxidizing bacteria isolated from swine wastewater treatment system. Water Sci Technol 59:2405–2410

Li Z, Feiten HJ, Chang D, Duetz WA, Van Beilen JB, Witholt B (2001) Preparation of (R)- and (S)-N-protected 3-hydroxypyrrolidines by hydroxylation with *Sphingomonas* sp. HXN-200, a highly active, regio- and stereoselective, and easy to handle biocatalyst. J Org Chem. 66(25):8424-8430. doi: 10.1021/jo015826d

Licht D, Johansen SS, Arvin E, Ahring BK (1997) Transformation of indole and quinoline by *Desulfobacterium indolicum* (DSM 3383). Appl Microbiol Biotechnol 47:167–172

Lobastova TG, Sukhodolskaya GV, Nikolayeva VM, Baskunov BP, Turchin KF, Donova MV (2004) Hydroxylation of carbazoles by *Aspergillus flavus* VKM F-1024. FEMS Microbiol Lett 235:51–56

Mahmoudi N., Ciceron L., Franetich J-F., Farhati K., Silvie O., Eling W., Sauerwein R., Danis M., Mazier D., Derouin F. In
100

vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage *Plasmodium* spp. *Antimicrob. Agents Chemother.* 2003. V. 47. N 8. P.2636-2639.

Martens R, Wetzstein HG, Zadrazil F, Capelari M, Hoffmann P, Schmeer N. Degradation of the fluoroquinolone enrofloxacin by wood-rotting fungi. *Appl. Environ. Microbiol.* 1996. 62: 4206-4209.

Martinsen B, Horsberg TE. Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (*Salmo salar*) held in seawater at 10°C. *Antimicrob. Agents Chemother.* 1995. 39: 1059-1064.

McGuirk PR, Jefson MR, Mann DD, Elliott NC, Chang P, Cisek EP, Cornell CP, Gootz TD, Haskell SL, Hindahl MS, LaFleur LJ, Rosenfeld MJ, Shryock TR, Silvia AM, Weber FH. Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofoxacin, a new quinolone antibacterial agent for veterinary medicine. *J. Med. Chem.* 1992. 35: 611-620.

McKay VA, Thompson SJ, Tran PM, Goodall KJ, Brimble MA, Barker D. Stereoselective synthesis of 4-substituted 4-hydroxypiperidines via epoxidation–ring opening of 4-methylenepiperidines. *Synlett.* 2010. 17:2631–2635. doi: 10.1055/s-0030-1258778

Mendoza A, Perez-Silanes S, Quiliano M, Pabón A, Galiano S, Gonzalez G, Garavito G, Zimic M, Vaisberg A, Aldana I, Monge A, Deharo E (2011) Aryl piperazine and pyrrolidine as antimalarial agents. Synthesis and investigation of structure-activity relationships. *Exp Parasitol.* 128(2):97-103. doi: 10.1016/j.exppara.2011.02.025

Mihovilovic MD, Spina M, Stanetty P (2005) Synthesis and yeast - mediated bioreduction of α -keto- β -lactams bearing a functionalized and rigid side chain. *Arkivoc.* 5:33-44. doi: 10.3998/ark.5550190.0006.504

Miller IM, Wittreich JM, Cook T, Vogel R. The safety and efficacy of topical norfloxacin compared with chloramphenicol for the treatment of external ocular bacterial infections. *Eye* 6: 111-114.

Mitchell MA. Enrofloxacin. *J. Exotic Pet Med.* 2006. 15: 66-69.

Modyanova L.V., Duduchava M.R., Piskunkova N.F., Grishina G.V., Terent'ev P.B., Parshikov I.A. Microbiological Transformation of Piperidine and Pyridine Derivatives. *Cheminform.* 2010. V.31, N 12.
<http://dx.doi.org/10.1002/chin.200012047>

Modyanova LV, Duduchava MR, Piskunkova NF, Grishina GV, Terentyev PB, Parshikov IA (1999) Microbial

transformations of piperideine and pyridine derivatives. Chemistry of Heterocyclic Compounds. 33(5):580-586. doi: 10.1007/BF02324642

Modyanova LV, Vorobyeva LI, Shibilkina OK, Dovgilevich EV, Terentyev PB, Kost AN (1990) Microbial transformation of nitrogen-containing heterocyclic compounds. I. Hydroxylation of isomeric methyl- and dimethylpyridines by microscopic fungi. Biotehnologiya 1990(3):24–27

Mountfield RJ, Hopper DJ (1998) The formation of 1-hydroxymethylnaphthalene and 6-hydroxymethylquinoline by both oxidative and reductive routes in *Cunninghamella elegans*. Appl Microbiol Biotechnol 50:379–383

Mugnaini C, Pasquini S, Corelli F. The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry. Curr. Med. Chem. 2009. 16: 1746-1767.

Müller R, Rappert S (2010) Pyrazines: occurrence, formation and biodegradation. Appl Microbiol Biotechnol 85:1315–1320

Muregi FW, Ishih A (2010) Next-generation antimalarial drugs: hybrid molecules as a new strategy in drug design. Drug Dev Res 71:20–32

Murphy CD, Clark BR, Amadio J. Metabolism of fluoroorganic compounds in microorganisms: impacts for the

environment and the production of fine chemicals. Appl. Microbiol. Biotechnol. 2009. 84: 617-629.

Neef G, Eder U, Petzoldt K, Seeger A, Wieglepp H (1982) Microbial hydroxylation of β -carboline derivatives. J Chem Soc Chem Commun 1982:366–367

Nguyen QC, Nguyen TT, Yougnia R, Gaslonde T, Dufat H, Michel S, Tillequin F. Acronycine derivatives: a promising series of anti-cancer agents. Anti-Cancer Agents Med. Chem. 2009. 9: 804-815.

Nojiri H, Habe H, Omori T (2001) Bacterial degradation of aromatic compounds via angular dioxygenation. J Gen Appl Microbiol 47:279–305

Obata H, Kawahara H, Sugiyama A (1997) Microbial transformation of carbazole to indole-3-acetic acid by *Flavobacterium* sp. OCM-1. Biosci Biotechnol Biochem 61:525–526

Oliphant C.M., Green G.M. Quinolones: a comprehensive review. Am. Fam. Physician. 2002. V. 65. N 3. P.455-464.

Oshima T, Kawai S, Egami F (1965) Oxidation of indole to indigotin by *Pseudomonas indoloxidans*. J Biochem 58:259–263

Osorio-Lozada A, Tovar-Miranda R, Olivo HF (2008) Biotransformation of *N*-piperidinylacetophenone with *Beauveria*

bassiana ATCC-7159. J Mol Catal B: Enzym. 55(1-2):30-36. doi: 10.1016/j.molcatb.2007.12.026

Ouchiyama N, Zhang Y, Omori T, Kodama T (1993) Biodegradation of carbazole by *Pseudomonas* spp. CA06 and CA10. Biosci Biotechnol Biochem 57:455–460

Pacorel B, Leung SC, Stachulski AV, Davies J, Vivas L, Lander H, Ward SA, Kaiser M, Brun R, O'Neill PM (2010) Modular synthesis and *in vitro* and *in vivo* antimalarial assessment of C-10 pyrrole Mannich base derivatives of artemisinin. J Med Chem. 53:633–640. doi: 10.1021/jm901216v

Parshikov I. A., Freeman J. P., Lay J. O. Jr., Moody J. D., Williams A. J., Beger R. D., Sutherland J. B. Metabolism of the veterinary fluoroquinolone sarafloxacin by the fungus *Mucor ramannianus*. Journal of Industrial Microbiology and Biotechnology. 2001b. V. 26. P.140-144.

Parshikov I. A., Heinze T. M., Moody J. D., Freeman J. P., Williams A. J., Sutherland J. B. The fungus *Pestalotiopsis guepini* as a model for biotransformation of ciprofloxacin and norfloxacin. Applied Microbiology and Biotechnology. 2001a. V. 56. P.474-477.

Parshikov I. A., Moody J. D., Freeman J. P., Lay J.O., Williams A. J., Heinze T. M., Sutherland J. B. Formation of

conjugates from ciprofloxacin and norfloxacin in cultures of *Trichoderma viride*. // Mycologia. 2002. V. 94. N 1. P.1-5.

Parshikov I.A., Freeman J.P., Lay J.O. Jr., Beger R.D., Williams A.J., Sutherland J.B. Microbiological transformation of enrofloxacin by the fungus *Mucor ramannianus*. 100th General Meeting of American Society for Microbiology, Los Angeles, California, May 21-25, 2000b, Q-180.

Parshikov I.A., Freeman J.P., Lay J.O. Jr., Moody J.D., Williams A.J., Sutherland J.B. Formation of unusual ciprofloxacin and norfloxacin conjugates by the fungus *Trichoderma viride*. 100th General Meeting of American Society for Microbiology, Los Angeles, California, May 21–25, 2000a, Q-181.

Parshikov I.A., Freeman J.P., Lay J.O. Jr., Moody J.D., Williams A.J., Beger R.D., Sutherland J.B. Metabolism of the veterinary fluoroquinolone sarafloxacin by the fungus *Mucor ramannianus*. 100th General Meeting of American Society for Microbiology, Los Angeles, California, May 21–25, 2000c, Q-182.

Parshikov I.A., Freeman J.P., Lay J.O., Beger R.D., Williams A.J., Sutherland J.B. Microbiological transformation of enrofloxacin by the fungus *Mucor ramannianus*. Applied and Environmental Microbiology. 2000d. V. 66. N 6. P.2664-2667.

Parshikov I.A., Freeman J.P., Williams A.J., Moody J.D., Sutherland J.B. Microbiological transformation of *N*-acetylphenothiazine by fungi. 99th General Meeting of American Society for Microbiology, Chicago, Illinois, May 30 – June 3, 1999b, Q-258.

Parshikov I.A., Heinze T.M., Moody J.D., Freeman J.P., Williams A.J., Sutherland J.B. The fungus *Pestalotiopsis guepini*. as a model for biotransformation of ciprofloxacin and norfloxacin. 101th General Meeting of American Society for Microbiology, Orlando, Florida, May 20-24, 2001c, Q-191.

Parshikov I.A., Heinze T.M., Moody J.D., Williamson J.S. Microbial transformation of the Antimalarial drug Primaquine (8-Aminoquinoline) by *Beauveria bassiana*. 102th General Meeting of American Society for Microbiology, Salt Lake City, Utah, May 19-23, 2002c, Q-83.

Parshikov I.A., Heinze T.M., Williams A.J., Moody J.D., Freeman J.P., Sutherland J.B. Biotransformation of the antibacterial agent cinoxacin by the fungus *Beauveria bassiana*. 102th General Meeting of American Society for Microbiology, Salt Lake City, Utah, May 19-23, 2002a, Q-78

Parshikov I.A., Modyanova L.V., Dovgilevich E.V., Terentyev P.B., Vorobyeva L.I., Grishina G.V. Microbiological Transformations of Nitrogen-Containing Heterocyclic Compounds. Part 3. Microbiological Synthesis of Hydroxy

Derivatives of 1-Benzoylpiperidine and 1-Benzoylpyrrolidine.
Cheminform. 2010b, v.24, N 38,
<http://dx.doi.org/10.1002/chin.199338068>

Parshikov I.A., Moody J.D., Heinze T.M., Freeman J.P.,
Williams A.J., Sutherland J.B. Transformation of cinoxacin by
Beauveria bassiana. // FEMS Microbiol. Lett. 2002b. V. 214.
P.133-136.

Parshikov I.A., Sutherland J.B. The use of *Aspergillus niger* cultures for biotransformation of terpenoids. Process Biochemistry. 2014. V.49. N 12. P. 2086-2100.
<http://dx.doi.org/10.1016/j.procbio.2014.09.005>

Parshikov I.A., Terent'ev P.B., Modyanova L.V.
Microbiological Transformations of Nitrogen-Containing Heterocycles. Cheminform. 2010. V.26, N 30.
<http://dx.doi.org/10.1002/chin.199530292>

Parshikov I.A., Terent'ev P.B., Piskunkova N.F., Gracheva R.A., Bulakhov G.A. Microbial Transformation of 4-Phenylpyrrolidone-2 Derivatives by Micellar Fungi. Cheminform. 2010a. V. 29. N 1. <http://dx.doi.org/10.1002/chin.199801032>

Parshikov I.A., Terentyev P.B., Modyanova L.V.,
Duduchava M.R., Dovgilevich E.V., Butakoff K.A.
Microbiological Transformation of 9-Amino-1,2,3,4,5,6,7,8-

octahydroacridine. *Cheminform*. 2010c, v.26, N 10,
<http://dx.doi.org/10.1002/chin.199510042>

Parshikov IA, Freeman JP, Williams AJ, Moody JD, Sutherland JB (1999) Biotransformation of *N*-acetylphenothiazine by fungi. *Applied Microbiology and Biotechnology*. 52:553–557

Parshikov IA, Modyanova LV, Dovgilevich EV, Terentyev PB, Vorobyeva LI, Grishina GV (1992) Microbiological transformation of nitrogen-containing heterocyclic compounds. 3. Microbiological synthesis of hydroxy derivatives of 1-benzoylpiperidine and 1-benzoylpyrrolidine. *Chemistry of Heterocyclic Compounds*. 28(2):159-162. doi: 10.1007/BF00473936

Parshikov IA, Netrusov AI, Sutherland JB Microbial transformation of antimalarial terpenoids. *Biotechnology Advances*. 2012. 30(6):1516–1523. doi: 10.1016/j.biotechadv.2012.03.010

Parshikov IA, Terent'ev PB, Modyanova LV, Duduchava MR, Dovgilevich EV, Butakov KA (1994a) Microbial transformations of 9-amino-1,2,3,4,5,6,7,8-octahydroacridine. *Chemistry of Heterocyclic Compounds* 30:627–628

Parshikov IA, Terentyev PB, Modyanova LV (1994b) Microbial transformation of nitrogenous heterocycles. *Khim Geterotsikl Soed* 1994(11-12):1510–1535.

Parshikov, I.A., Heinze T.M., Williams A.J., Moody J.D., Freeman J.P., Sutherland J.B. Biotransformation of the antibacterial agent cinoxacin by the fungus *Beauveria bassiana*. FEMS Microbiology Letters. 2002b. V.214. P.133-136.

Parshikov I.A., Muralieedharan K.M., Avery M.A., Williamson J.S. Hydroxylation of 10-deoxoartemisinin by *Cunninghamella elegans*. Journal of Natural Products. 2004a. V.67. N 9. P. 1595-1597.

Parshikov I.A., Muralieedharan K.M., Avery M.A., Williamson J.S. Transformation of artemisinin by *Cunninghamella elegans*. Applied Microbiology and Biotechnology. 2004b. V.64. N 6. P. 782-786.

Parshikov I.A., Miriala B., Avery M.A., Williamson J.S. Hydroxylation of 10-deoxoartemisinin to 15-hydroxy-10-deoxoartemisinin by *Aspergillus niger*. Biotechnology Letters. 2004c. V.26. N 7. P. 607-610.

Parshikov I.A., Miriyala B., Muralieedharan K.M., Illendula A., Avery M.A., Williamson J.S. Biocatalysis of the antimalarial artemisinin by *Mucor ramannianus strains*. Pharmaceutical Biology. 2005. V.43. N 7. P. 579-582.

Parshikov IA, Miriyala B, Muraleedharan KM, Avery MA, Williamson JS. Microbial transformation of artemisinin to 5-hydroxyartemisinin by *Eurotium amstelodami* and *Aspergillus*

niger. Journal of Industrial Microbiology and Biotechnology. 2006. V.33. N 5. P. 349-352.

Peters W. The evolution of tafenoquine—antimalarial for a new millennium. J Roy Soc Med. 1999. 92:345–352

Petersen M, Kiener A (1999) Biocatalysis: preparation and functionalization of *N*-heterocycles. Green Chem. 1:99–106. doi: 10.1039/A809538H

Petersen M, Kiener A (1999) Biocatalysis: preparation and functionalization of *N*-heterocycles. Green Chem 1:99–106

Prachayasittikul S, Treeratanapiboon L, Ruchirawat S, Prachayasittikul V (2009) Novel activities of 1-adamantylthiopyridines as antibacterial, antimalarials and anticancers. EXCLI J 8:121–129

Prasad GS, Girisham S, Reddy SM (2009) Studies on microbial transformation of meloxicam by fungi. J Microbiol Biotechnol 19:922–931

Radic Z, Sit RK, Kovarik Z, Berend Z, Garcia E, Zhang L, Amitai G, Green C, Radic B, Fokin VV, Sharpless KB, Taylor P (2012) Refinement of structural leads for centrally acting oxime reactivators of phosphorylated cholinesterases. J Biol Chem. 287(15):11798–11809. doi: 10.1074/jbc.M111.333732

Rajini KS, Aparna P, Sasikala C, Ramana CV (2011) Microbial metabolism of pyrazines. Crit Rev Microbiol 37:99–112

Ray L, Das Gupta C, Majumdar S K (1983)
Microbiological reduction of quinonone to quinidine. Appl Environ
Microbiol 45:1935–1936

Refaie FM, Esmat AY, Gawad SMA, Ibrahim AM,
Mohamed MA (2005) The antihyperlipidemic activities of 4(3H)-
quinazolinone and two halogenated derivatives in rats. Lipids
Health Dis 4:22, p. 1–11

Ren D, Zhang X, Yan K, Yuan S, Lu X (2006) Studies on
the degradation of indole using white rot fungus. Fresenius
Environ Bull 15:1238–1243

Resnick SM, Torok DS, Gibson DT (1993) Oxidation of
carbazole to 3-hydroxycarbazole by naphthalene 1,2-dioxygenase
and biphenyl 2,3-dioxygenase. FEMS Microbiol Lett 113:297–302

Richardson DW, Wyso EM (1960) Human pharmacology
of guanethidine. Annals of the New York Academy of Sciences.
88: 944-955. doi: 10.1111/j.1749-6632.1960.tb20086.x

Rigos G, Troisi GM. Antibacterial agents in Mediterranean
finfish farming: a synopsis of drug pharmacokinetics in important
euryhaline fish species and possible environmental implications.
Rev. Fish Biol. Fisheries. 2005. 15: 53-73.

Rios R, Ibrahim I, Vesely J, Sundén H, Córdova A (2007)
Organocatalytic asymmetric 5-hydroxypyrrolidine synthesis: a

highly enantioselective route to 3-substituted proline derivatives.
Tetrahedron Lett. 48:8695-8699. doi: 10.1016/j.tetlet.2007.10.028

Robicsek A., Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nature Med. 2006. 12: 83-88.

Rocco F (2003) Quinine: Malaria and the Quest for a Cure that Changed the World. Harper Collins, New York, 348 p

Röger P, Erben A, Lingens F (1990) Microbial metabolism of quinoline and related compounds. IV. Degradation of isoquinoline by *Alcaligenes faecalis* Pa and *Pseudomonas diminuta* 7. Biol Chem Hoppe-Seyler 371:511–513

Romanova NN, Tallo TG, Bundel YG (1995) Synthesis and stereochemistry of chiral azetidin-2-ones and azetidine-2-thiones. 3. Stereodirected construction of the β-lactam fragment of the thienamycin molecule. Chem Heterocycl Compd. 31(2):223-226. doi: 10.1007/BF01169684

Rothenburger S, Atlas RM (1993) Hydroxylation and biodegradation of 6-methylquinoline by pseudomonads in aqueous and nonaqueous immobilized-cell bioreactors. Appl Environ Microbiol 59:2139–2144

Rui L, Reardon KF, Wood TK (2005) Protein engineering of toluene *ortho*-monooxygenase of *Burkholderia cepacia* G4 for

regiospecific hydroxylation of indole to form various indigoid compounds. *Appl Microbiol Biotechnol* 66:422–429

Sabbour MS, El Bokl MA, Osman LM. Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI). *Infection* 12: 377-380.

Saliba KJ, Kirk K (1998) Clotrimazole inhibits the growth of *Plasmodium falciparum* in vitro. *Trans Roy Soc Trop Med Hyg* 92:666–667

Sappal R., Chaudhary R.K., Sandhu H.S., Sidhu P.K. Pharmacokinetics, urinary excretion and plasma protein binding of danofloxacin following intravenous administration in buffalo calves (*Bubalus bubalis*). *Vet. Res. Commun.* 2009. V. 33. N 7. P.659-667.

Sarma P.S. Norfloxacin: a new drug in the treatment of falciparum malaria. *Ann. Intern. Med.* 1989. V. 111. P.336-337.

Sasikala C, Ramana CV, Rao PR (1994) Photometabolism of heterocyclic aromatic compounds by *Rhodopseudomonas palustris* OU 11. *Appl Environ Microbiol* 60:2187–2190

Schellhorn C. Classification of quinolones by V. Andriole. *Infection*. 1998. V. 26. N 1. P.46.

Schwarz G, Bauder R, Speer M, Rommel TO, Lingens F (1989) Microbial metabolism of quinoline and related compounds.

II. Degradation of quinoline by *Pseudomonas fluorescens* 3,
Pseudomonas .putida 86, and *Rhodococcus* spec B1. Biol Chem
Hoppe-Seyler 370:1183–1189

Seebacher W, Weis R (2011) Novel antimalarial 3-azabicyclo[3.2.2]nonane derivatives. European patent N 2301627A1, 30.03.2011.

Sellyei B., Varga Z., Szentesi-Samu K., Kaszanyitzky E., Magyar T. Antimicrobial susceptibility of *Pasteurella multocida* isolated from swine and poultry. // Acta Vet. Hung. 2009. V. 57. N 3. P.357-367.

Sharma PC, Jain A, Jain S, Pahwa R, Yar MS. Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects. J. Enz. Inhib. Med. Chem. 2010. 25: 577-589.

Sharma R, Samadhiya P, Srivastava SD, Srivastava SK (2011) Synthesis and biological activity of 2-oxo-azetidine derivatives of phenothiazine. Org Commun. 4(2):42-51.

Shibuya H, Kitamura C, Maehara S, Nagahata M, Winarno H, Simanjuntak P, Kim H-S, Wataya Y, Ohashi K (2003) Transformation of *Cinchona* alkaloids into 1-N-oxide derivatives by endophytic *Xylaria* sp. isolated from *Cinchona pubescens*. Chem Pharm Bull 51:71–74

Shih TL, Liang MT, Wu KD, Lin CH (2011) Synthesis of polyhydroxy 7- and *N*-alkyl-azepanes as potent glycosidase inhibitors. *Carbohydr Res.* 346(2):183–190. doi: 10.1016/j.carres.2010.11.014

Shih TL, Yang RY, Li ST, Chiang CF, Lin CH (2007) Expedited synthesis of tri- and tetrahydroxyazepanes from D-(-)-quinic acid as potent glycosidase inhibitors. *J Org Chem.* 72:4258–4261. doi: 10.1021/jo070058x

Shukla OP (1984) Microbial transformation of pyridine compounds. *Proc Ind Acad Sci Chem Sci* 93:1143–1153

Shukla OP (1986) Microbial transformation of quinoline by a *Pseudomonas* sp. *Appl Environ Microbiol* 51:1332–1342

Shukla OP (1987) Microbiological transformation and biodegradation of quinoline: isolation and characterization of quinoline-degrading bacteria and identification of early intermediates. *Biol Mem (Lucknow)* 13:115–131

Siebers-Wolff S, Arfmann H-A, Abraham W-R, Kieslich K (1993) Microbiological hydroxylation and N-oxidation of cinchona alkaloids. *Biocatalysis* 8:47–58

Silva E.O., Carvalho T.C., Parshikov I.A., Santos R.A., Emery F.S., Furtado N.A.J.C. Cytotoxicity of lapachol metabolites produced by probiotics. *Letters in Applied Microbiology.* 2014. V.59. N 1. P. 108-114.

Singh P, Sachdeva S, Raj R, Kumar V, Mahajan MP, Nasser S, Vivas L, Gut J, Rosenthal PJ, Feng TS, Chibale K (2011) Antiplasmodial and cytotoxicity evaluation of 3-functionalized 2-azetidinone derivatives. *Bioorg Med Chem Lett.* 21(15):4561-4563. doi: 10.1016/j.bmcl.2011.05.119

Singh P, Singh P, Kumar M, Gut J, Rosenthal PJ, Kumar K, Kumar V, Mahajan MP, Bisetty K. Synthesis, docking and *in vitro* antimalarial evaluation of bifunctional hybrids derived from β -lactams and 7-chloroquinoline using click chemistry. *Bioorg. Med. Chem. Lett.* 2012 V. 22. N 1. P.57-61. doi: 10.1016/j.bmcl.2011.11.082

Sisca TS, Heel RC, Romankiewicz JA. Cinoxacin—A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections. *Drugs.* 1983. 25: 544-569.

Srairi D, Maurey G (1987) Hydroxylations microbiologiques de pyrrolidinones-2. *Bull Soc Chim Fr.* 2:297-301.

Stephan I, Tshisuaka B, Fetzner S, Lingens F (1996) Quinaldine 4-oxidase from *Arthrobacter* sp Rü61a, a versatile procaryotic molybdenum-containing hydroxylase active towards N-containing heterocyclic compounds and aromatic aldehydes. *Eur J Biochem* 236:155–162

Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR.
Mechanism of action of nalidixic acid: purification of *Escherichia coli* *nalA* gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Nat. Acad. Sci. USA. 1977. 74: 4767-4771.

Sukul P, Spiteller M (2007) Fluoroquinolone antibiotics in the environment. Rev Environ Contam Toxicol. 191:131–162. doi: 10.1007/978-0-387-69163-3_5

Sun H, Millar KM, Yang J, Abboud K, Horenstein BA (2000) A new asymmetric route to substituted piperidines: synthesis of *N*-alkyl-3,4-dihydroxy-5-alkylpiperidines. Tetrahedron Lett. 41(16):2801-2804. doi: 10.1016/S0040-4039(00)00267-7

Sutherland JB, Cross EL, Heinze TM, Freeman JP, Moody JD (2005) Fungal biotransformation of benzo[*f*]quinoline, benzo[*h*]quinoline, and phenanthridine. Appl Microbiol Biotechnol 67:405–411.

Sutherland JB, Evans FE, Freeman JP, Williams AJ (1996) Biotransformation of quinoxaline by *Streptomyces badius*. Lett Appl Microbiol 22:199–201.

Sutherland JB, Evans FE, Freeman JP, Williams AJ, Deck J, Cerniglia CE (1994b) Identification of metabolites produced

from acridine by *Cunninghamella elegans*. Mycologia 86:117–120.

Sutherland JB, Freeman JP, Heinze TM, Moody JD, Parshikov IA, Williams AJ, Zhang D (2001) Oxidation of phenothiazine and phenoxazine by *Cunninghamella elegans*. Xenobiotica 31:799–809.

Sutherland JB, Freeman JP, Williams AJ (1998a) Biotransformation of isoquinoline, phenanthridine, phthalazine, quinazoline, and quinoxaline by *Streptomyces viridosporus*. Appl Microbiol Biotechnol 49:445–449

Sutherland JB, Freeman JP, Williams AJ, Cerniglia CE (1994a) N-oxidation of quinoline and isoquinoline by *Cunninghamella elegans*. Exp Mycol 18:271–274

Sutherland JB, Freeman JP, Williams AJ, Deck J (1998b) Metabolism of cinnoline to N-oxidation products by *Cunninghamella elegans* and *Aspergillus niger*. J Ind Microbiol Biotechnol 21:225–227

Sutherland JB, Freeman JP, Williams AJ, Deck J (1999) Biotransformation of phthalazine by *Fusarium moniliforme* and *Cunninghamella elegans*. Mycologia 91:114–116.

Sutherland JB, Heinze TM, Pearce MG, Deck J, Williams AJ, Freeman JP (2009) Biotransformation of acridine by *Mycobacterium vanbaalenii*. Environ Toxicol Chem 28:61–64.

Sutherland JB, Heinze TM, Schnackenberg LK, Freeman JP, Williams AJ (2011) Biotransformation of quinazoline and phthalazine by *Aspergillus niger*. J Biosci Bioeng 111:333–335.

Taggart JV, Earle DP, Berliner RW, Welch WJ, Zubrod CG, Jailer JW, Kuhn BH, Norwood J, Shannon JA (1948) Studies on the chemotherapy of the human malarias. V. The antimalarial activity of quinacrine. J Clin Invest 27:93–97.

Takayama T, Umemiya H, Amada H, Yabuuchi T, Shiozawa F, Katakai H, Takaoka A, Yamaguchi A, Endo M, Sato M (2010) Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: structure, synthesis, and SAR. Bioorg Med Chem Lett 20:108–111.

Taniguchi T, Ogasawara K (2000) A diastereocontrolled synthesis of (+)-febrifugine: a potent antimalarial piperidine alkaloid. Org Lett. 2(20):3193–3195. doi: 10.1021/o1006384f

Terent'ev PB, Zilberstein TM, Borisenko AA, Shmorgunov VA, Piskunkova NF, Grishina GV (2003) Transformation of 1,2,5,6-tetrahydropyridines with mycellar fungi. Chemistry of Heterocyclic Compounds. 39(7):885-894. doi: 10.1023/A:1026142220384

Terent'ev PB, Parshikov IA, Grishina GV, Piskunkova NF, Chumakov TI, Bulakhov GA (1997) Hydroxylation of the double bond in 1-benzyl-3-methyl- Δ^3 -piperidine by mycelium fungi.

Chemistry of Heterocyclic Compounds. 33(5): 619-620. doi: 10.1007/BF02291950

Teuscher G, Teuscher E (1965) 5-Hydroxyindole-3-acetic acid as a metabolic product of indole-3-acetic acid produced by ergot fungus. Phytochemistry 4:511–515.

Thibodeaux CJ, Chang WC, Liu HW (2012) Enzymatic chemistry of cyclopropane, epoxide, and aziridine biosynthesis. Chem Rev. 112(3):1681-1709. doi: 10.1021/cr200073d

Vale N, Moreira R, Gomes P (2009) Primaquine revisited six decades after its discovery. Eur J Med Chem 44:937–953.

Van Herwijnen R, de Graaf C, Govers HAJ, Parsons JR (2004) Estimation of kinetic parameter for the biotransformation of three-ring azaarenes by the phenanthrene-degrading strain *Sphingomonas* sp LH128. Environ Toxicol Chem 23:331–338.

Vickers S, Polksy SL (2000) The biotransformation of nitrogen containing xenobiotics to lactams. Curr Drug Metab. 1(4):357-389. doi: 10.2174/1389200003338929

Vickers S, Polksy SL (2000) The biotransformation of nitrogen containing xenobiotics to lactams. Curr Drug Metab 1:357–389.

Vorobyeva LI, Parshikov IA, Dorre M, Dovgilevich EV, Modyanova LV, Terentyev PB, Nikishova NG. Microbial transformations of nitrogen-containing heterocyclic compounds.

II. Hydroxylation of ethylpyridines by microscopic fungi.
Biotekhnologiya 1990. N 4. P.24–27.

Waldau D, Methling K, Mikolasch A, Schauer F.

Characterization of new oxidation products of 9*H*-carbazole and structure related compounds by biphenyl-utilizing bacteria. Appl Microbiol Biotechnol. 2009. 81:1023–1031.

Walsh JJ, Coughlan D, Heneghan N, Gaynor C, Bell A. A novel artemisinin-quinine hybrid with potent antimalarial activity. Bioorg Med Chem Lett. 2007. 17:3599–3602.

Walsh JJ, Coughlan D, Heneghan N, Gaynor C, Bell A (2007) A novel artemisinin–quinine hybrid with potent antimalarial activity. Bioorg Med Chem Lett. 17:3599–3602. doi: 10.1016/j.bmcl.2007.04.054

Wang F, Langley R, Gulten G, Dover LG, Besra GS, Jacobs WR, Sacchettini JC (2007) Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med 204:73–78

Waring MJ, Wakelin LPG, Lee JS (1975) A solvent-partition method for measuring the binding of drugs to DNA. Application to the quinoxaline antibiotics echinomycin and triostin A. Biochim Biophys Acta 407:200–212

Watson GK, Houghton C, Cain RB (1974) Microbial metabolism of the pyridine ring. The hydroxylation of 4-

hydroxypyridine to pyridine 3,4-diol (3,4-dihydroxypyridine) by 4-hydroxypyridine 3-hydroxylase. Biochem J 140:265–276

Watt G., Shanks G. D., Edstein M.D., Pavanand K., Webster H.K., Wechgritaya S. Ciprofloxacin treatment of drug-resistant falciparum malaria. // J. Infect. Dis. 1991. V. 164. P.602-604.

Weintraub PM, Sabol JS, Kane JM, Borcherding DR (2003) Recent advances in the synthesis of piperidones and piperidines. Tetrahedron. 59(17):2953–2989. doi: 10.1016/S0040-4020(03)00295-3

Wetzstein H.-G. Biologische Abbaubarkeit der Gyrasehemmer: Chinolone in der Umwelt. Pharmazie in unserer Zeit. 2001. V. 30, P.450–457.

Wetzstein H.-G. Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob. Agents Chemother. 2005. V. 49. N 10. P.4166-4173.

Wetzstein H.-G., Dalhoff A., Karl W. BAY 12-8039, a new 8-methoxyquinolone, is degraded by the brown rot fungus *Gloeophyllum striatum*. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. - Toronto, Canada, 1997. - Abstract F 157. P.172.

Wetzstein H.-G., Hallenbach W. Tuning of antibacterial activity of a cyclopropyl fluoroquinolone by variation of the substituent at position C-8. *J. Antimicrob. Chemother.* 2011. 66: 2801-2808.

Wetzstein H.-G., Schneider J., Karl W. Metabolite proving fungal cleavage of the aromatic core part of a fluoroquinolone antibiotic. *AMB Express* 2012. V. 2. N 3. doi:10.1186/2191-0855-2-3.

Wetzstein H.-G., Schneider J., Karl W. Patterns of metabolites produced from the fluoroquinolone enrofloxacin by basidiomycetes indigenous to agricultural sites. *Appl. Microbiol. Biotechnol.* 2006. V. 71. P.90-100.

Wetzstein H.-G., Stadler M., Tichy H.-V., Dalhoff A., Karl W. Degradation of ciprofloxacin by basidiomycetes and identification of metabolites generated by the brown rot fungus *Gloeophyllum striatum*. *Appl. Environ. Microbiol.* 1999. V. 65. N 4. P.1556-1563.

Wetzstein H-G, Schmeer N, Karl W. Degradation of the fluoroquinolone enrofloxacin by the brown rot fungus *Gloeophyllum striatum*: Identification of metabolites. *Appl. Environ. Microbiol.* 1997. Volume: 63 Pages: 4272-4281.

Wetzstein H-G, Schneider J, Karl W. Comparative biotransformation of fluoroquinolone antibiotics in matrices of

agricultural relevance. In: Veterinary Pharmaceuticals in the Environment (Henderson KL, Coats JR, eds). 2010. Oxford University Press, New York.

Wieser M, Fujii N, Yoshida T, Nagasawa T. Carbon dioxide fixation by reversible pyrrole-2-carboxylate decarboxylase from *Bacillus megaterium* PYR2910. Eur J Biochem. 1998. 257:495–499.

Williams A.J., Deck J.D., Freeman J.P., Chiarelli M.P., Adjei T.M., Heinze T.M., Sutherland J.B. Biotransformation of flumequine by the fungus *Cunninghamella elegans*. Chemosphere. 2007. V. 67. P.240-243

Williams A.J., Parshikov I.A., Moody J.D., Heinze T.M., Freeman J.P., Sutherland J.B. The metabolism of two antibacterial agents, norfloxacin and sarafloxacin by the saprobic fungus *Trichoderma* sp. during growth on the rice hulls. 101th General Meeting of American Society for Microbiology, Orlando, Florida, May 20-24, 2001, Q-195.

Williams, A. J., I. A. Parshikov, J. D. Moody, T. M. Heinze, and J. B. Sutherland. Fungal transformation of an antimicrobial fluoroquinolone drug during growth on poultry litter materials. The Journal of Applied Poultry Research. . 2004. 13: 235-240.

Williamson J.S., Parshikov I.A., Avery M.A.
Biotransformations of Artemisinin. in: - Recent Progress in
Medicinal Plants, (Phytochemistry and Pharmacology). 2007, V.
17, P. 115-138.

Willumsen PA, Johansen JE, Karlson U, Hansen BM.
Isolation and taxonomic affiliation of N-heterocyclic aromatic
hydrocarbon-transforming bacteria. Appl Microbiol Biotechnol.
2005. 67:420–428.

Willumsen PA, Nielson JK, Karlson U. Degradation of
phenanthrene-analogue azaarenes by *Mycobacterium gilvum* strain
LB307T under aerobic conditions. Appl Microbiol Biotechnol.
2001. 56:539–544.

Wright AD, Goclik E, König GM, Kaminsky R, Lepadins
D-F: antiplasmodial and antitrypanosomal decahydroquinoline
derivatives from the tropical marine tunicate *Didemnum* sp. J Med
Chem. 2002 45(14):3067-3072. doi: 10.1021/jm0110892

Yang W, Davis PJ. Microbial models of mammalian
metabolism: biotransformations of *N*-methylcarbazole using the
fungus *Cunninghamella echinulata*. Drug Metab Dispos. 1992.
20:38–46.

Yasuhaba A, Akiba-Goto M, Fujishiro K, Uchida H,
Uwajima T, Aisaka K. Production of aldehyde oxidases by

microorganisms and their enzymatic properties. J Biosci Bioeng. 2002. 94:124–129.

Yoshida T, Sada Y, Nagasawa T. Bioconversion of 2,6-dimethylpyridine to 6-methylpicolinic acid by *Exophiala dermatitidis* (Kano) de Hoog DA5501 cells grown on *n*-dodecane. Appl Microbiol Biotechnol. 2010. 86:1165–1170.

Zefirov NS, Agapova SR, Bulakhova IM, Terent'ev PB, Vasyukova NI, Modyanova LV. Microbiological transformation of nitrogen-containing heterocyclic compounds. Izv Ross Akad Nauk Ser Biol. 1995. (3):367–371.

Zefirov NS, Agapova SR, Terentiev PB, Bulakhova IM, Vasyukova NI, Modyanova LV. Degradation of pyridine by *Arthrobacter crystallopoietes* and *Rhodococcus opacus* strains. FEMS Microbiol Lett. 1994. 118:71–74.

Zefirov NS, Terentiev PB, Modyanova LV, Dovgilevich EV. Regio- and stereoselective hydroxylation of some nitrogen heterocyclic compounds by microorganisms. Ind J Chem. 1993 32B:54–57.

CONTENTS

Introduction	3
Chapter 1. Microbial transformation of saturated nitrogenous heterocyclic compounds	9
1.1. Microbial transformation of aziridine derivatives.....	10
1.2. Microbial transformation of azetidine derivatives.....	11
1.3. Microbial transformation of pyrrolidine and its derivatives.....	14
1.4. Microbial transformation of piperidine and its derivatives...	18
1.5. Microbial transformation of azepane, azocane and their derivatives.....	24
Chapter 2. Microbial transformation of azaarenes.....	28
2.1. Transformation of single-ring azaarenes.....	29
2.2. Transformation of quinoline, alkylquinolines, and isoquinoline.....	35
2.3. Transformation of benzodiazines and benzothiazines.....	44
2.4. Transformation of benzoquinolines.....	47
2.5. Transformation of phenazine and phenothiazine.....	51
2.6. Transformation of indole, carbazole, and the carbolines.....	52
Chapter 3. Microbial transformations of quinolones and related drugs.....	60
3.1. Transformations of first-generation quinolones and their analogs.....	61
3.2. Transformation of second-generation quinolones.....	66
3.3. Transformation of third-generation quinolones.....	71
3.4. Transformation of fourth-generation quinolones.....	77
Conclusion.....	79
References.....	80



Researches were focused on the biotransformation processes of phenothiazine and its derivatives and the ways of converting them into more physiologically active compounds. In time of transformation of fluoroquinolones were observed the processes of N-oxidation, acetylation, formylation, decarboxylation, conjugation, and also the destruction of piperazine rings, with the formation of less toxic compounds.

Later, researches had been involves the study of biotransformation (hydroxylation) of antimalarial artemisinin and its analogs for further the synthesis of new derivatives which could be used as new drugs. More than eighty research manuscripts, review articles, patents and abstracts of communications on scientific meetings on topics of microbiology, organic chemistry and biotechnology, have been published.

**Primedia E-launch LLC
2137 Ash Grove Way Dallas,
TX 75228
<http://www.isbnservices.com/>**

